Dysregulated FOXO1 activity drives skeletal muscle intrinsic dysfunction in amyotrophic lateral sclerosis

Mónica Zufiría^{1,2,*}, Oihane Pikatza-Menoio^{1,2,\$*}, Maddi Garciandia-Arcelus^{1,*}, Xabier 3 Bengoetxea^{1,†}, Andrés Jiménez^{1,2,†}, Amaia Elicegui^{1,2,\$}, Maria Levchuk¹, Olatz Arnold-García^{1,2}, 4 Pablo Iruzubieta^{1,2,3}, Jon Ondaro^{1,2}, Uxoa Fernández-Pelayo¹, Mikel Muñoz-Oreja^{1,2,4}, Ana 5 Aiastui^{1,2,5}, José Manuel García-Verdugo^{2,6,7}, Vicente Herranz-Pérez^{2,6,7}, Miren Zulaica^{1,2}, Juan 6 José Poza^{1,2,3}, Rebeca Ruiz-Onandi^{8,9}, Roberto Fernández-Torrón^{1,2,3}, Juan Bautista Espinal³, 7 Mario Bonilla¹⁰, Ana Lersundi^{10,11}, Gorka Fernández-Eulate^{3,12,13}, Javier Riancho^{2,14,15}, Ainara 8 Vallejo-Illarramendi^{1,2,4}, Ian James Holt^{1,2,16,17}, Amets Sáenz^{1,2}, Edoardo Malfatti^{18,19}, Stéphanie 9 Duguez^{20,21}, Lorea Blázquez^{1,2,16}, Adolfo López de Munain^{1,2,3,22,23,24}, Gorka Gerenu^{1,2,16,25,#}, 10 Francisco Gil-Bea^{1,2,16,26,#}, Sonia Alonso-Martín^{1,2,\$#@} 11 ¹Neurosciences Area, Biogipuzkoa Health Research Institute, 20014 Donostia/San Sebastian, 12 13 Spain ²CIBERNED, ISCIII (CIBER, Carlos III Institute, Spanish Ministry of Sciences and 14 Innovation), 28031, Madrid, Spain 15 16 ³Department of Neurology, Donostialdea Integrated Health Organization, Osakidetza Basque 17 Health Service, 20014 Donostia/San Sebastian, Spain 18 ⁴Department of Pediatrics, Faculty of Medicine and Nursery, University of the Basque Country UPV/EHU, 20014, Donostia/San Sebastian, Spain 19 20 ⁵Cell Culture Platform, Biodonostia Health Research Institute, 20014 Donostia/San Sebastian, 21 Spain ⁶Laboratory of Comparative Neurobiology, Cavanilles Institute of Biodiversity and 22 23 Evolutionary Biology, University of Valencia, 46980 Paterna, Spain 24 ⁷Department of Cell Biology, Functional Biology and Physical Anthropology, University of 25 Valencia, 46100 Burjassot, Spain 26 ⁸Department of Pathological Anatomy, Galdakao-Usansolo University Hospital, Osakidetza 27 Basque Health Service, 48960 Galdakao, Spain 28 ⁹Department of Medical-Surgical Specialties, Faculty of Medicine and Nursery, University of the Basque Country UPV/EHU, 48940 Leioa, Spain 29 30 ¹⁰Department of Traumatology and Orthopedic Surgery, Donostialdea Integrated Health 31 Organization, Osakidetza Basque Health Service, 20014 Donostia/San Sebastian, Spain 32 ¹¹Department of Surgery, Faculty of Medicine and Nursery, University of the Basque Country 33 UPV/EHU, 20014 Donostia/San Sebastián, Spain 34 ¹²Nord/Est/Ile-de-France Neuromuscular Reference Center, Institut de Myologie, Pitié-35 Salpêtrière Hospital, 75012 Paris, France

- 36 ¹³Institut Necker-Enfants Malades, INSERM U1151, BioSPC (ED562), Université Paris Cité,
- **37** 75015 Paris, France.
- ¹⁴Department of Neurology, Hospital de Sierrallana-IDIVAL, 39300 Torrelavega, Cantabria,
 Spain
- ¹⁵Department of Psychiatry and Medicine, Faculty of Medicine, University of Cantabria, 39011
 Santander, Spain.
- 42 ¹⁶IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain
- ¹⁷Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of
 Neurology, Royal Free Campus, London, NW3 2PF, UK
- ¹⁸Université Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France Hôpital Henri Mondor, 94010 Créteil, France
- ¹⁹Paris Reference Center for Neuromuscular Disorders, APHP Henri Mondor University
 Hospital, 94010 Créteil, France
- 49 ²⁰Personalised Medicine Centre, School of Medicine, Ulster University, Derry BT47 6SB, UK
- ²¹Northern Ireland Center for Stratified Medicine, Biomedical Sciences Research Institute,
 Londonderry, UK
- ²²Department of Neurosciences, Faculty of Medicine and Nursery, University of the Basque
 Country UPV/EHU, 20014 Donostia/San Sebastian, Spain
- ²³Department of Medicine, Faculty of Health Sciences, University of Deusto, 48007 Bilbao,
 Spain
- ²⁴Biodonostia Health Research Institute, 20014 Donostia/San Sebastian, Spain
- ²⁵Department of Physiology, Faculty of Medicine and Nursery, University of the Basque
 Country UPV/EHU, 48940 Leioa, Spain
- ²⁶Department of Health Sciences, Public University of Navarra (UPNA), 31006 Pamplona,
 Spain
- ^{\$}Present address: Stem Cells and Aging Group, Biogipuzkoa Health Research Institute, 20014
 Donostia/San Sebastian, Spain
- 63 *Equal contribution
- 64 †Equal contribution
- 65 [#]Equal contribution
- 66
- 67 [@]Correspondence to:
- 68 Sonia Alonso-Martin (sonia.alonsomartin@bio-gipuzkoa.eus) T. +34 943006029

69

70

71 Author Contributions

ALM, FG-B and SA-M designed the study in collaboration with MZuf (in vitro and metabolic 72 73 experiments) and GG (Drosophila experiments). MZuf, OP-M, MG-A, AE, ML, MZul, AS, GG 74 and SA-M performed experiments with ALS patient-derived primary cultures and MZuf, OP-M, 75 MG-A, XB, PI, JO, UF-P, MM-O, GF-E, AV-I, IJH and FG-B with 8220 immortalised human control myoblasts. MZuf, MG-A, GF-E and AA performed SeaHorse experiments. JMG-V and 76 77 VH-P designed and performed TEM experiments. OA, LB and FG-B analysed NGS data. PI, 78 JJP, RR-O, RF-T, JBE, MB, AL, GF-E, JR, EM, SD and ALM clinically identified and 79 characterised patients and collected muscle samples. AJ and GG performed and analysed 80 Drosophila experiments. ALM, FG-B and SA-M supervised and coordinated all work. ALM, 81 FG-B and SA-M contributed to the preparation of the manuscript.

82

83 ABSTRACT

84 Amyotrophic Lateral Sclerosis (ALS) is a multisystemic neurodegenerative disorder, with 85 accumulating evidence indicating metabolic disruptions in the skeletal muscle preceding disease 86 symptoms, rather than them manifesting as a secondary consequence of motor neuron (MN) 87 degeneration. Hence, energy homeostasis is deeply implicated in the complex physiopathology 88 of ALS and skeletal muscle has emerged as a key therapeutic target. Here, we describe intrinsic abnormalities in ALS skeletal muscle, both in patient-derived muscle cells and in muscle cell 89 90 lines with genetic knockdown of genes related to familial ALS, such as TARDBP (TDP-43) and 91 FUS. We found a functional impairment of myogenesis that parallels defects of glucose 92 oxidation in ALS muscle cells. We identified FOXO1 transcription factor as a key mediator of 93 these metabolic and functional features in ALS muscle, via gene expression profiling and 94 biochemical surveys in TDP-43 and FUS silenced muscle progenitors. Strikingly, inhibition of 95 FOXO1 mitigated the impaired myogenesis in both the genetically modified and the primary 96 ALS myoblasts. In addition, specific in vivo conditional knockdown of TDP-43 or FUS 97 orthologs (TBPH or caz) in Drosophila muscle precursor cells resulted in decreased innervation 98 and profound dysfunction of motor nerve terminals and neuromuscular synapses, accompanied 99 by motor abnormalities and reduced lifespan. Remarkably, these phenotypes were partially 100 corrected by *foxo* inhibition, bolstering the potential pharmacological management of muscle 101 intrinsic abnormalities associated with ALS. The findings demonstrate an intrinsic muscle 102 dysfunction in ALS, which can be modulated by targeting FOXO factors, paving the way for 103 novel therapeutic approaches that focus on the skeletal muscle as complementary target tissue.

104

105 Keywords

106 Amyotrophic lateral sclerosis; myogenesis; glycolysis; TDP-43; FUS; FOXO1.

107

108 INTRODUCTION

109 Amyotrophic lateral sclerosis (ALS) is a devastating disorder characterised by a progressive 110 degeneration of upper and lower motor neurons (MN) that leads to the death of the patient 111 within an average of 36 months from onset [10, 78]. Major symptoms, including weakness, 112 motor disability, paralysis, and ultimately death, arise from the progressive waste of the skeletal 113 muscle. Although MN loss and the subsequent dismantling of the neuromuscular junctions 114 (NMJ) are considered the primary cause of muscle atrophy, recent evidence suggests that 115 muscle pathology may be an active player in ALS disease. These data include pathological 116 accumulation of phospho-TDP-43 within muscle fibres [42], as well as in distal axons within 117 intramuscular nerve bundles of patients [28]. Indeed, studies carried out in SOD1 mouse models 118 have evidenced that early metabolic alterations occur in the skeletal muscle before the onset of 119 MN degeneration [12, 13, 33, 51]. Moreover, the overexpression of mutated SOD1 restricted 120 exclusively to skeletal muscle cells is able to induce some of the ALS phenotypes, including 121 loss of spinal MNs [37, 84]. Collectively, these findings support a central role of the skeletal 122 muscle in ALS pathogenesis. This aligns with the disease-modifying effect that vigorous 123 physical exercise appears to exert on ALS, as described in genetic and epidemiologic studies 124 [18, 24].

125 Muscle fibre homeostasis in adulthood is fundamentally supported by intrinsic repair mechanisms that involve a sequence of metabolically fine-tuned steps, ranging from the 126 127 activation and proliferation of skeletal muscle resident stem cells (known as satellite cells) to the 128 differentiation and fusion into multinucleated syncytia, the myotubes, which will mature into 129 new myofibers [59]. Several works have shown that satellite cells isolated from ALS patients 130 exhibit changes in different myogenic markers [23, 57, 69], as well as a reduced ability to form 131 mature myotubes under in vitro conditions [57, 69]. Likewise, myogenic defects have also been 132 reported in cultured myoblasts derived from mouse models expressing mutations in either 133 SOD1 [36, 80] or VAPB [80]. Although these myogenic defects may be legitimately considered 134 secondary to changes in the denervated stem cell niche, the recent discovery of the 135 moonlighting activity of TARDBP (a major ALS-causative gene) in muscle regeneration has 136 bolstered the argument for the implication of myogenesis in the pathophysiology of ALS [81]. In that study, the protein expressed by TARDBP gene, TDP-43, was proven to be essential for 137 138 skeletal muscle formation and regeneration by recruiting specific mRNAs that encode 139 sarcomeric proteins into cytoplasmic amyloid-like granules [81]. In this line, Le Gall and 140 collaborators demonstrated a neurotoxic paracrine role of muscle cells via secretion of 141 extracellular vesicles in recipient cells such as the MNs, with a FUS-dependent mechanism [17]. 142 Furthermore, two French families carrying a missense (G376V) and a C terminal frameshift

143 variant of TDP 43 have lately been identified to be affected by autosomal dominant

144 myopathies [14, 90].

In light of this evidence, we postulate that abnormalities of muscle turnover in ALS might stem
from intrinsic metabolic defects in muscle progenitors that eventually aggravate muscle wasting
in ALS.

148 Based on the growing hypothesis that muscle defects contribute to MN degeneration through a 149 dying-back mechanism [64], we sought to decipher the mechanisms underlying myogenic 150 derangements in ALS. Our goal was to identify therapeutic targets that can mitigate or alleviate neuronal degeneration. For this purpose, we studied the contribution of two major ALS genes, 151 152 TARDBP and FUS, in the metabolic regulation during myogenesis and differentiation, by using 153 human immortalised myoblasts with induced loss-of-function (LoF) of such genes and ALS 154 patient-derived primary myoblasts. Moreover, we analysed the functional in vivo consequences 155 in Drosophila melanogaster ALS models with muscle-specific LoF of TBPH and caz, human 156 TARDBP and FUS ortholog genes, respectively. Indeed, we found a general reduction in TDP-157 43 and FUS proteins which associated with impaired differentiation and increased expression of 158 atrophic markers in patient-derived muscle cells, as well as repressed glycolysis as a consistent 159 metabolic feature linking energy defects with the impaired myogenic capacity induced by TDP-160 43 or FUS LoF. In addition, gene expression surveys and rescue experiments identified dysregulation of FOXO1 transcription factor as a mediator of the myogenic defects caused by 161 162 TDP-43 or FUS knockdown. Inhibition of FOXO1 not only mitigated myogenic and metabolic 163 abnormalities in ALS myoblast cells but also in other two MN disorders with muscle 164 involvement, such as Spinal Muscular Atrophy (SMA) or Spinal Bulbar Muscular Atrophy 165 (SBMA). Furthermore, it also rescued ALS-associated phenotypes in *Drosophila* models that 166 bear the conditional knockdown of *TBPH* and *caz* genes specifically in muscle progenitor cells. Strikingly, muscle-nerve connections were disrupted in these fly models but corrected at the 167 168 synapse level by foxo inhibition. Therefore, in this study, we propose FOXO transcription 169 factors as pharmacological targets for the treatment of ALS through the mitigation of skeletal 170 muscle metabolic and functional defects, which could improve the associated MN function.

171 MATERIAL AND METHODS

172 Patients, clinical management and muscle biopsies

173 Neurologists from the ALS Unit of Donostia University Hospital were in charge of performing 174 diagnoses, patients' examination and muscle biopsies. Samples and clinical data from patients 175 included in this study were provided by the Basque Biobank (www.biobancovasco.org) and 176 processed following standard procedures with appropriate approval by the Clinical Research 177 Ethics Committees of the Basque Country and Donostia University Hospital (codes: ALM-178 EMP-2015-01, PI2016075, PI2019198). Informed consent was obtained from all the subjects. 179 This research project was conducted following the requirements of The European Regulation of 180 Data Protection and Digital Rights guarantee. All samples were anonymized, only keeping the 181 necessary gender and age information.

182 All muscle biopsies were performed using the open minor surgery technique at the neurologist's 183 consulting room, except for the *post mortem*, which was recovered at the autopsy room. 21 184 muscle biopsies were used in this study, as summarised next (Table 1): 8 Controls (CTRL), 30-185 75 years-old; 3 Familial ALS (fALS), 45-71 years-old; 5 Sporadic ALS (sALS), 47-66 years-186 old; 3 MN disorders (SMA3, caused by mutations in SMN1; SBMA, also known as Kennedy's 187 disease, related to pathogenic GCC expansions in the androgen receptor; CMT4, Charcot-188 Marie-Tooth type 4, a recessive and demyelinating disease); and 2 muscular disorders with 189 protein aggregates (sporadic Inclusion Body Myositis-IBM and a vacuolar myopathy related to 190 Valosin-Containing Protein-VCP). CMT4 myoblasts were provided by the MYOBANK-AFM 191 (Myology Institute) (Table 1).

192 Haematoxylin and Eosin Staining in histological cryosections

193 Muscle biopsies were recovered and cleared of vessels and connective tissue. Several pieces 194 from each biopsy were snap-frozen in liquid nitrogen-cooled isopentane to be processed for 195 histological analysis. 8 µm cryosections were obtained and fixed in 4% paraformaldehyde 196 (PFA) and processed for Haematoxylin and Eosin staining as previously described [65]. The 197 histological preparations were mounted with DPX Mountant (Sigma-Aldrich) and scanned at 198 10X magnification on Pannoramic MIDI II (3DHistech).

S	Sample	Diagnosis	Onset	Genetics	Sex	Age Onset	Age Biopsy	Status Biopsy	Age Death	Muscle	CNS - Autopsy
C	CTRL-1	Control	NA	NP	М	-	30-35 yr	alive	alive	Deltoideus	NP
C	CTRL-2	Control	NA	NP	М	-	30-35 yr	alive	alive	Deltoideus	NP
C	CTRL-3	Control	NA	NP	М	-	40-45 yr	alive	alive	Gastrocnemius	NP
C	CTRL-4	Control	NA	NP	F	-	46-50 yr	alive	alive	Deltoideus	NP
C	CTRL-5	Control	NA	NP	М	-	46-50 yr	alive	alive	Vastus lateralis	NP
C	CTRL-6	Control	NA	NP	F	-	70-75 yr	alive	alive	Deltoideus	NP
C	CTRL-7	Control	NA	NP	М	-	70-75 yr	alive	alive	Gluteus medius	NP
C	CTRL-8	Control	NA	NP	М	-	70-75 yr	alive	alive	Deltoideus	NP
f	ALS_1	Familial ALS	Spinal	HET pathogenic variant in <i>TARDBP</i> : (c.1055A>G p.[N352S])	М	65-69 yr	70-75 yr	alive	70-75 yr	Tibialis anterior	NP

199	Table 1.	Clinical	characteristics	of p	participants	and thei	r biological	samples.

fALS_2	Familial ALS	Spinal	Unknown	М	40-45 yr	40-45 yr	alive	46-50 yr	Tibialis anterior	NP
fALS_3	Familial ALS/FTD	Spinal	Unknown	F	65-69 yr	65-69 yr	post mortem	65-69 yr	Vastus lateralis	General neuronal loss and Gliosis Intracytoplasmic Inclusions: TDP-43, p62, Aβ, TAU
sALS_1	Sporadic ALS	First MN	HET variant of unknown significance in <i>FUS</i> (3´UTR) HET variant of unknown significance in <i>ALS2</i> (c.1641- 4T>G)	М	55-59 yr	60-64 yr	alive	wheel-chair	Tibialis anterior	NP

sALS_2	Sporadic ALS	Bulbar	HET variant of unknown significance in <i>SOD1</i> : (c.73- 108T>A)	F	60-64 yr	65-69 yr	palliative	65-69 yr	Biceps	MN loss in spinal cord Gliosis Intracytoplasmic Inclusions: TDP-43, p62
sALS_3	Sporadic ALS	Spinal	Unknown	М	60-64 yr	60-64 yr	post mortem	60-64 yr	Tibialis anterior	MN loss in spinal cord Gliosis Intracytoplasmic Inclusions: TDP-43
sALS_4	Sporadic ALS	Spinal	Unknown	М	46-50 yr	46-50 yr	alive	46-50 yr	Tibialis anterior	NP
sALS_5	Sporadic ALS	Spinal	Unknown	М	56-60 yr	56-60 yr	alive	56-60 yr	Tibialis anterior	NP
SMA3	Spinal Muscular Atrophy type 3	NA	Unknown	М	NA	30-35 yr	alive	NA	Deltoideus	NP
SBMA	Spinal Bulbar Muscular Atrophy (Kennedy's	NA	Unknown	М	NA	60-64 yr	alive	NA	Deltoideus	NP

disease)

CMT4	Charcot- Marie-Tooth type 4	NA	Unknown	F	NA	10-15 yr	alive	NA	Latissimus dorsi	NP
IBM	Sporadic Inclusion Body Myositis	NA	Unknown	М	NA	70-75 yr	alive	NA	Deltoideus	NP
VCP	Vacuolar Myopathy related to VCP (no ALS/FTD- related)	NA	HET pathogenic variant in VCP c.472A>G (p.Met158Val)	М	NA	40-45 yr	alive	NA	Deltoideus	NP
CTRL, cont	CTRL, control; ALS, Amyotrophic Lateral Sclerosis; fALS, familial; sALS, sporadic; FTD, Frontotemporal Dementia; VCP, Valosin-containing Protein									

200	CTRL, o	control; A	ALS, Amyotrop	hic Later	al Scleros	is; fALS, familia	ıl; sALS	, sporadic; FT	D, Fron	totemporal	Dementia;	VCP, Valosin-contai	ning Prote	ein
201	NA,	not	available;	NP,	not	performed;	F,	female;	М,	male;	HET,	heterozygous;	yr,	years.

202 Cell culture assays

203 Primary myoblasts from patients' muscle biopsies

204 Human proximal muscle biopsies were minced and explants were cultured to obtain myogenic 205 precursors in a monolayer as described previously [61]. To obtain highly purified myoblasts 206 (CD56+), primary cultures were sorted by immunomagnetic selection based on the presence of 207 the early cell surface marker CD56 (separator and reagents from Miltenyi Biotec, Bergisch 208 Gladbach, Germany). Cells' myogenicity was confirmed by Desmin immunolabeling, and all 209 cultures were used at *passages* 3 and 4. Finally, myoblasts were grown up to the desired density in an incubator at 37° C, with 5% CO₂ and a humidified atmosphere. The proliferation medium 210 211 used from this moment was the Skeletal Growth Medium (SGM, PromoCell), supplemented as 212 stated below. For *post mortem* samples, different reports have demonstrated that muscle 213 progenitor cells, while retaining their regenerative capacity, grow and differentiate as well as 214 those obtained from fresh biopsies [30, 50, 54].

215 Immortalised human control myoblasts (line 8220)

216 The immortalised human myoblast control cell line 8220 was generated at the Platform for the 217 Immortalization of Human Cells / Myology Institute (Paris, France) and kindly provided by Dr. 218 Vincent Mouly [29]. These myoblasts were grown and transduced as previously described [29], 219 with minor modifications. Briefly, the proliferation medium consisted of SGM supplemented 220 with 10% FBS, 1% Glutamax and 1% gentamicin (all from Gibco-Invitrogen). Gene silencing 221 was carried out by transduction with lentiviral particles containing short hairpin RNA (shRNA). 222 The plasmids used to create these particles were: SHC001 (shRNA Empty Vector Control 223 Plasmid DNA), TRCN000016038 (human, TARDBP MISSION shRNA), TRCN0000288639 224 (human, FUS MISSION shRNA), TRCN0000010333 (human, FOXO MISSION shRNA) 225 (MISSION® pLKO.1-Pure) (all from Sigma-Aldrich). Viral particles were produced and titled 226 by the Viral Vector Unit of CNIC (Madrid, Spain). Myoblasts were seeded in 6-well plates at a 227 density of 80,000 cells/well, and the next day viral particles were added at a MOI of 10. 24 228 hours after transduction, the medium was removed and replaced by fresh SGM proliferation 229 medium. To verify the degree of gene silencing, TDP-43 and FUS protein expression was 230 measured by Western blot.

231 Induction and assessment of myogenic differentiation

Either primary or immortalised myoblasts were cultured in SGM medium supplemented with 10% FBS, 1% Glutamax and 1% gentamicin, and differentiation occurred spontaneously without medium refreshing by cell-cell contact when cultures were at high confluence. The differentiation index was calculated as the percentage of nuclei in MyHC-positive cells out of

- the total (DAPI-positive) nuclei. The fusion index was calculated as the percentage of nuclei
- 237 fused into myotubes (MyHC-positive syncytia with at least two nuclei) out of the total nuclei.
- 238 Myogenicity was assessed as the percentage of MYOD-positive or MYOG-positive nuclei, out
- of the total nuclei. Over 3 wells and 3-10 fields were evaluated per each group.
- 240 2-Deoxy-D-glucose (2-DG) treatment

For Western blot analysis, cells were seeded at 60% of confluence in 6-well plates in 2 mL of SGM, allowing them to adhere overnight (O/N). The next day, cells were treated with 100 μ M 2-DG and kept for 4 days, when untreated cells were at 100% of confluence. For immunofluorescence analysis, cells were seeded at 100% of confluence in μ -slide wells (Ibidi) in 60 μ l of SGM, and allowed to adhere O/N. The next day, cells were treated with 100 μ M 2-DG for 48h.

247 Proliferation curves

248 2,000 cells/well of primary human myoblasts or 2,500 cells/well per silenced human control
249 myoblasts (shRNA, shTDP-43 and shFUS) were plated in μ-slide wells (Ibidi), and fixed at
250 three time points: day 1, day 3 and day 5. DAPI staining was used to quantify cell numbers at
251 all times. Images were taken with ZEISS LSM 900 confocal microscope, and quantification of
252 DAPI+ cells was performed with ImageJ v2.9.

253 *iFOXO1 treatment*

33 nM (IC50) of FOXO1 inhibitor *AS1842856* (Astella Pharma; Shelleck; # S8222) was used in all *in vitro* experiments. For Seahorse experiments, myoblasts were treated with iFOXO1 inhibitor after seeding them in a 96-well XF cell culture microplate (Agilent) for 24 h. For differentiation experiments, after fusion, silenced or ALS patient-derived myoblasts were kept with the inhibitor for 8 days. For proliferation experiments, cells were treated with iFOXO1 or the corresponding amount of DMSO, refreshing it every 3 days. Finally, for *in vivo* experiments in *Drosophila*, 30 µM iFOXO1 was diluted in the food.

261 *Drosophila melanogaster* models and functional assays

262 One Drosophila strain where Cabeza (caz) gene is silenced in muscle cells (UAS-Dicer2-icaz-263 Mef2-GAL4, iCaz) and three Drosophila strains where TBPH gene is silenced at different locus in muscle cells were generated: UAS-Dicer2-iTBPHattp40-Mef2-GAL4 (iTBPHattp40); UAS-264 (iTBPH^{p(GD6943)}): 265 Dicer2-iTBPHp(GD6943)-Mef2-GAL4, and UAS-Dicer2*iTBPHp(pkk108354)-Mef2-GAL4*, (iTBPH^{pkk108354}) were generated. As control flies, the strain 266 267 UAS-Dicer2-+-Mef2-GAL4 was used. To generate these genotypes, stocks from Vienna Stock Center (VDRC, Austria) (caz, #100291; TBPH^{GD6943} #38377 and TBPH^{pkk(108354)} #104401) and 268

Bloomington Stock Centre (Indiana, USA) (TBPHattiP40 #39014 and Dicer2-Mef2 #25756) were 269 270 acquired. Flies were housed at 23°C, 70% humidity and 12 h/12 h light/darkness cycle. For 271 longevity assays, one hundred adult flies (five per tube) were selected from each strain. Dead 272 flies were counted every 2 days. Kaplan-Meier method was used to plot the results. A log-rank 273 test was used to analyse results and Bonferroni correction for multiple comparisons. For 274 locomotor activity, adult flies on days 5, 10 and 15 were analysed in groups of five. They were 275 placed in a tube with a line drawn outside the tube at 8 cm height from the bottom. The number 276 of flies that passed the line in 10 seconds was counted (3 trials per tube). Adult pharate survival 277 was expressed as a percentage of the adult flies counted over the total number of pupae in each 278 tube where adult pharate survival of control flies was around 100%. 6 tubes were counted per group in i*TBPH*^{*pkk*(108354)} flies. 279

280 Western blotting

281 Bulk protein extraction from cell cultures was done with a sample buffer containing 62 mM Tris 282 (pH 7.5), 5% glycerol, 2% SDS, 5mg/ml bromophenol blue and 5% β-mercaptoethanol. In some 283 experiments, cell fractionation was carried out using the NE-PER kit (Thermo Scientific, 284 Catalog Code 78833) before adding the sample buffer. Samples were run in CriterionTM gels (Bio-Rad, Life Sciences, CA, USA) by SDS-PAGE electrophoresis. Proteins were transferred to 285 BioTraceTM Nitrocellulose membranes (Pall Corporation, NY, USA). Primary antibodies are 286 287 summarised in Supplementary Table 1. Secondary antibodies conjugated to Alexa fluor plus 288 fluorophores (Invitrogen) were diluted to 1/10,000 in TBS-T (tris buffered saline with 1:1000 289 Tween 20) with 5% BSA (both from Sigma-Aldrich). Bands were visualised using iBright 290 FL1000 Imaging System and quantified with Image Studio Lite v5.2. β-actin or β-tubulin were 291 used as loading control. Results were expressed as optical density (O.D.).

292 Immunofluorescence

293 Myoblasts or myotubes grown on μ -slide or μ -plate wells (Ibidi) were fixed after several 294 washes in PBS, with 4% paraformaldehyde (PFA) for 10 min. After several washes, fixed cells 295 were blocked in a solution containing 5% BSA, 2% horse serum (HS, Gibco-Invitrogen), 0.02% 296 sodium azide and 0.5% Triton X-100 in TBS-T, for 30 min. Cells were incubated with primary 297 antibodies O/N at 4°C diluted in blocking solution. Primary antibodies are summarised in 298 Supplementary Table 1. The next day, cells were rinsed three times in TBS-T. Secondary 299 antibodies conjugated to Alexa fluor plus fluorophores (Invitrogen) were diluted to 1/1,000 in 300 blocking solution and incubated for 2 h at room temperature (RT) in the dark. DAPI was added 301 together with the secondary antibody to visualise the cell nuclei. ZEISS LSM 900 laser 302 scanning confocal microscope (Carl Zeiss, Inc., Germany) and Fluorescent Nikon 80i 303 microscope were used to analyse the immunostaining. Levels of nuclear protein expression were

assessed by quantifying the integrated densities of nuclei by ImageJ v2.9 using DAPI staining to delimit nuclei. For the assessment of MYOD-, MYOG- and FOXO1-positive nuclei, integrated density values above the cut-off point (set as the value of mean +1*SD of control cells) were considered positive. For the assessment of nuclear depletion of TDP-43 or FUS, nuclei with integrated density values below the cut-off point (set as the value of mean -1*SD of control cells) were considered negative. To evaluate the nuclear expression of FOXO3, the integrated density values of each nucleus were quantified and plotted.

311 Transmission electron microscopy

312 Cells were postfixed in 1% osmium tetroxide, 7% sucrose in 0.1 M PB for 30 min at RT, 313 washed in deionized water, and partially dehydrated in ethanol. Cells were then stained in 2% 314 uranyl acetate in 70% ethanol in the dark for 2 h 30 min at 4°C. Cells were further dehydrated in 315 ethanol, and infiltrated O/N in Durcupan ACM epoxy resin (Fluka, Sigma-Aldrich, St. Louis, 316 USA). Following resin hardening, embedded cell cultures were detached from the chamber slide 317 and glued to resin blocks. Serial semi-thin sections (1.5 μ m) were cut with an Ultracut UC-7 318 ultramicrotome (Leica, Heidelberg, Germany) and mounted onto glass microscope slides and 319 lightly stained with 1% toluidine blue. Selected semi-thin sections were glued with Super Glue-320 3, Loctite (Henkel, Düsseldorf, Germany) to resin blocks and subsequently detached from the 321 glass-slides by repeated freezing (in liquid nitrogen) and thawing. Ultra-thin sections (70-80 322 nm) were obtained with the ultramicrotome from detached semi-thin sections, and further 323 stained with lead citrate (Reynolds' solution) [60]. Finally, cells were imaged at 80 kV on a FEI Tecnai G² Spirit transmission electron microscope (FEI Europe, Eindhoven, Netherlands) 324 325 equipped with a Morada CCD digital camera (Olympus Soft Image Solutions GmbH, Münster, 326 Germany).

327 Histopathological analysis of Drosophila melanogaster muscle

328 Immunofluorescence was used to study the motoneurons and the integrity of the neuromuscular junction in the indirect flight muscles of the iTBPH^{pkk108354} and control *Drosophila* models. 329 Flies were anaesthetised with CO₂-enriched air. Fly thoraces were isolated and immersed into 330 331 70% EtOH for 1 min. and placed in PBS for dissection. Samples were fixed with 4% PFA for 332 30 min. After 3 washes in PBS with 0.5% Triton X-100 (PBS-T), samples were immersed into 333 liquid nitrogen for 10 seconds and transferred into cold PBS. Thoraces were divided 334 longitudinally, washed 4 x 5 min in PBS-T, and incubated for 30 mins in blocking solution (5% 335 BSA and 0.02% NaN₃ in PBS-T) at RT. Subsequently, thoraces were incubated O/N at 4°C with 336 the primary antibody solution (HRP and nc82 (Supplementary Table 1) in blocking solution at 337 4°C. After 4 x 20 min washes with PBS-T, samples were incubated O/N at 4°C with the 338 secondary antibodies conjugated to Alexa fluor plus fluorophores (Invitrogen) and Invitrogen[™]

Alexa FluorTM 647 Phalloidin 1:1000 in blocking solution. Samples were mounted in ProLongTM Diamond Antifade Mountant (Invitrogen). Images were obtained in a confocal microscope LS900 (Zeiss) by z-stack scanning (total thickness of 15 μ m with a step size of 0.5 µm per slice) of the whole-mount thoraces (halves). Quantification of muscle area covered by HRP staining was carried out by using ImageJ v2.9, whereas quantification of nc82-positive synaptic boutons size was performed by using SynPAnal software [11].

345 **RNA-seq analysis**

346 RNA preparation and RNA-seq performance

Total RNA was extracted from three independent experimental replicates using the RNeasy Mini Kit (Ref. 74104, QIAGEN), followed by DNase I treatment. RNA integrity (3 *shRNA*, 3 *shTDP-43*, 3 *shFUS*) was assessed (Agilent 2100 Bioanalyzer) before ribosomal RNA depletion (Illumina Ribo-Zero Plus) and library preparation following a Stranded Full-length Total RNA procedure. Sequencing was performed on Illumina NextSeq2000 platform at a sequencing depth of at least 20M paired-end 100 nucleotide long reads (PE100). After sequencing, raw reads were filtered to remove adaptor sequences and low-quality reads (phred quality score below Q33).

354 RNA-seq data processing and analysis

355 RNA-seq reads were quasi-mapped to the reference transcriptome hg38 and the abundance of 356 each transcript was quantified using Salmon v.1.5.2. with default options for paired-end reads 357 [53]. Transcriptomes were indexed using the decoy-aware method in Salmon. Output quants 358 files were then processed in R Studio v.4.0.4 (RStudio Team, 2020; http://www.rstudio.com/). 359 Tximport package was used for non-normalized gene-level counts estimation from transcript-360 level counts using the "bias corrected counts without an offset" method [73]. R package 361 Normalization was performed using DEseq2 R package [34] to account for technical variability 362 and estimate size factors for accurate comparisons of gene expression between samples. A log2 363 fold change (Log2FC) threshold of greater than or equal to 1 (corresponding to a fold change of 364 2 or greater) was used to identify genes with statistically significant changes in expression after 365 adjusting for multiple testing using the Benjamini-Hochberg method (adjusted p-value < 0.001). 366 Functional pathway analysis was performed by Hallmark Pathway enrichment of differential 367 gene expression signatures using GSEA v.4.3.2 as previously described [77]. Classic weighting 368 was used as the enrichment statistics, and the permutation type was based on a gene set, using a 369 total of 1,000 iterations. A gene set is considered significantly enriched if its Normalized 370 Enrichment Score (NES) has a False Discovery Rate (FDR) p-value below 0.05 (Benjamini-371 Hochberg method) and a nominal p-value below 0.001. A GSEA score (based on multiplying

NES by $-\log_{10}$ FDR *p*-value) was calculated for each gene set, and their values for each gene list were plotted.

Transcription factor (TF) activity analysis was performed using ISMARA (Integrated System for Motif Activity Response), an online tool for automatically inferring regulatory networks from gene expression data [1]. Quality and adaptor trimmed fastq.gz RNA-seq files were uploaded to www.ismara.unibas.ch for processing, followed by sample average. For each enriched TF motif identified, the ISMARA score was calculated based on the z-score and average gene target expression change.

380 Data availability

381 Sequencing data have been deposited in GEO under accession code GSE227573.

382 Analysis of metabolic flux by SeaHorse

383 Metabolic pathways were studied using the Seahorse XF96 Extracellular Flux Analyzer 384 (Agilent). This equipment allows simultaneous study of the two main energy pathways, 385 mitochondrial respiration and glycolysis, in living cells and in real time. The analyzer measures 386 the ratio of oxygen consumption (OCR, Oxygen Consumption Rate), as an indicator of 387 mitochondrial respiration; and the ratio of extracellular acidification (ECAR, ExtraCellular 388 Acidification Rate), as an indicator of glycolysis and lactate production. The day before the 389 experiment, 15,000 primary myoblasts/well were seeded in a 96-well XF cell culture microplate 390 (Agilent) to reach 100% confluence. Before starting with the Glyco-stress experiment, media 391 was changed to glucose-free Seahorse XF MEM media (pH 7.4) (Agilent #103575-100) for 1 h, 392 and it was incubated at 37°C in an incubator without CO₂. Then, continuous measurements of 393 ECAR or OCR started. The data were normalised to cell number, which was measured by 394 Cresyl violet staining (0.1% solution for 15 min).

All metabolic tests using the Seahorse technique were performed when myoblasts were at a confluence of 100%. For the study of metabolism across muscle differentiation, cell seeding was carried out at different stages (myoblast, myocyte, 3-day, and 8-day myotubes) in order to obtain, in the same Seahorse plate, the different phases of the process. One hour before the test, cells were incubated at 37°C without CO_2 and in the glucose-free Seahorse XF MEM medium at pH 7.4.

401 Statistical analysis

402 Unless otherwise indicated, data were analysed and visualised by GraphPad Prism 7. Normality 403 was verified by the Shapiro-Wilks test (p<0.05). The choice of statistical test for group 404 comparisons was guided by the normality of the data distribution. For pairwise comparisons

- 405 between two groups, the Mann-Whitney U test was employed when the data exhibited a non-
- 406 normal distribution. In contrast, when the data followed a normal distribution, Student's t-test
- 407 was utilized. For comparisons involving more than two groups, one-way or two-way ANOVA
- 408 was followed by Dunnett's test. Unless otherwise indicated, the data are expressed as the mean
- 409 \pm the Standard Error of the Mean (SEM).

410

411 **RESULTS**

412 Myogenesis is impaired in ALS patients' cells independently of the motoneuron input

413 Histopathological analysis of muscle biopsies from age-matched control (CTRL) and ALS 414 patients, familial (fALS) and sporadic (sALS) patients, revealed chronic muscle affectation, 415 including myofiber atrophy, a few necrotic myofibers and either pyknotic or centralized nuclei 416 and cell infiltration in ALS cases (Supplementary Fig. 1). These findings indicate an already impaired muscle homeostasis across all ALS biopsies analysed. To further investigate these 417 418 alterations, we isolated muscle progenitor cells derived from 16 different subjects (8 CTRL, 3 419 fALS and 5 sALS cases; Table 1) and performed *in vitro* studies, devoid of inputs from MNs or 420 any other external stimuli able to modify the intrinsic properties of muscle cells. This approach 421 allowed for a comprehensive characterization of the myogenic process *per se* in ALS. We first 422 assessed the myogenic capacity of the expanded cells through differentiation assays. Our results 423 showed that most ALS myoblasts exhibited impaired differentiation, characterized by decreased 424 differentiation and fusion indices, as well as the formation of fewer and thinner myotubes, 425 compared to controls (Fig. 1a, b). Notably, one patient's myoblasts (fALS 2) demonstrated 426 elevated and comparable differentiation levels to controls. Interestingly, this patient's disease 427 progression was particularly slow (Table 1). It is noteworthy that myogenic differentiation 428 capacity is variable among controls, and this variability can be attributed to age, as there was a 429 negative correlation between differentiation index and age (Fig. 1c). However, in ALS patient 430 myoblasts myogenesis was affected regardless of age (Fig. 1c). Furthermore, myogenesis was 431 already impaired before differentiation and fusion events began, as evidenced by a significant 432 and consistent reduction in the expression of MYOD (Supplementary Fig. 2a), the key 433 transcription factor regulating myoblast differentiation, and myogenin (MYOG) 434 (Supplementary Fig. 2b), a crucial factor for myoblast differentiation and fusion. Consistently, fALS_2 cells did not display altered MYOG expression, which may account for the lack of 435 436 myogenic defects observed in these cells (Supplementary Fig. 2a).

On top of that, ALS-derived myoblasts exhibited decreased proliferation rates overall
(Supplementary Fig. 2c, d). Furthermore, we analysed regulators of atrophy pathways in the
skeletal muscle, such as the muscle-specific E3 ubiquitin ligases MURF1 and MAFbx/Atrogin1, and found an increase in ALS samples (Supplementary Fig. 2e), suggesting an activation of
the ubiquitin/proteasome system, leading to protein degradation.

Finally, the levels of the two proteins closely associated with ALS pathology, TDP-43 and FUS,
were evaluated. We observed a significant decrease in total TDP-43 levels and decreased FUS
levels by immunoblotting (Fig. 1d). Both TDP-43 and FUS are nuclear ribonucleoproteins that

shuttle between the nucleus and cytoplasm. Under certain pathological conditions or in response
to stress, they can accumulate in the cytoplasm [7]. However, in myoblasts, all the detectable
TDP-43 was located in the nucleus in patient- and control-derived myoblasts, including in cells
carrying a *TARDBP* mutation (fALS_1 patient) (Supplementary Fig. 3a), and while some FUS
was found in cytoplasmic granules, these were of equal abundance in CTRL and ALS
myoblasts (Supplementary Fig. 3b). Thus, the only discernible differences in TDP43 and FUS
were protein abundance.

Overall, these data reflect that muscle is intrinsically affected in ALS, independently of the
inputs from MNs and other environmental signals, and that downregulation of TDP-43 and FUS
may be contributing to this.

455 Dynamic expression of TDP-43 and FUS is required for myogenesis

456 To further understand the implication of TDP-43 and FUS in ALS-related myogenic alterations, 457 we knocked these genes down in an established human myoblast cell line (8220) to further 458 analyse changes in the myogenic capacity as well as the underlying mechanisms (Fig. 2a). 459 Lentiviral delivered shRNAs to TDP-43 or FUS decreased expression of the target gene by 80% 460 after 2 days (Fig. 2b). TARDBP silencing reduced FUS levels (40%) as well (Fig. 2b), implying 461 an upstream regulation of TDP-43 on FUS expression. This result aligns with previous CLIP-462 seq studies that identified FUS mRNA as a target of TDP-43 [56]. Both TDP-43- and FUS-463 silenced myoblasts displayed ultrastructure abnormalities revealed by transmission electron 464 microscopy (TEM) images (Supplementary Fig. 4a). Compared to scramble RNA-transduced 465 (shRNA) myoblasts, shTDP-43 myoblasts showed a rounded and enlarged shape accompanied 466 by mildly expanded nuclei. Organelles were arranged in perinuclear clusters, containing very short rough endoplasmic reticulum (RER) but a high number of smaller mitochondria 467 468 (Supplementary Fig. 4a, b). Similarly, shFUS myoblasts were elongated with abundant 469 mitochondria and dilated RER (Supplementary Fig. 4a, b). Despite these changes in cellular 470 morphology and distribution of intracellular components, all silenced myoblasts were viable.

471 We then studied the effect of TDP-43 or FUS silencing on myogenesis. First, we analysed the 472 expression of the myogenic factors MYOD and MYOG, which in most patient-derived primary 473 myoblasts and myotubes appeared downregulated (Supplementary Fig. 2a, b). Indeed, shTDP-474 43 and shFUS myogenic cells displayed a dramatic decrease in the total levels of both factors 475 (Fig. 2b). Both silenced myoblasts were more sensitive to growth factor deprivation, so when 476 differentiation was induced in such a way, shTDP-43 and shFUS myoblasts were not able to 477 survive the differentiation challenge, implying an extreme susceptibility to starvation. For this 478 reason, we switched to a more physiological myogenesis model, allowing spontaneous

479 differentiation and fusion by cell-to-cell contact once myoblasts reach 100% confluence. In this 480 scenario, control myoblasts differentiated and formed multinucleated myotubes (positive for 481 myosin heavy chain, MyHC) three days after reaching 100% confluence. In contrast, TDP-43 482 and FUS knockdown displayed a dramatic impairment in differentiation and fusion, with barely 483 any myotube formation (Fig. 2c). Furthermore, proliferation assays showed that the proliferative 484 capacity of shTDP-43 and shFUS myoblasts was strongly reduced as well (Fig. 2d). Finally, as 485 in patient-derived myoblasts (Supplementary Fig. 2e), we confirmed that the pro-atrophic 486 proteins Atrogin-1 and MURF1 were significantly increased in silenced myoblasts, particularly 487 in shTDP-43 myoblasts (Fig. 2e). Together, these results confirm an essential function of TDP-488 43 and FUS on myogenic differentiation and regeneration process.

489 It has been previously shown in mouse muscle progenitors that the nuclear exit of TDP-43 to 490 form cytoplasmic granules in early myotubes is required for muscle differentiation and 491 regeneration [81]. Thus, we performed different analyses to characterise TDP-43 and FUS 492 localization patterns along the human myogenic process. We studied the immortalised human 493 myoblast cell line 8220 [29] at five different stages: 30% confluence (proliferation); 100% confluence; fusion (myocytes); and early phases of differentiation until myotube formation 494 495 (days D3 and D8 post-fusion) (Supplementary Fig. 5a). The analysis of the expression of the 496 myogenic regulatory factors MYOD and MYOG showed an increase on MYOD levels prior to 497 first fusion events followed by a decrease during fusion and myotube maturation, while MYOG 498 appeared increased during fusion events and early phases of myotube formation (Supplementary 499 Fig. 5b), as previously reported in rodent and human myogenesis [47, 62]. Regarding TDP-43 500 and FUS localization across myogenesis, TDP-43 appears mainly limited to the nucleus 501 throughout the myogenic process, with a slighter increment in later stages, whereas nuclear FUS 502 decreases throughout differentiation, being totally absent in early myotubes at D8 503 (Supplementary Fig. 5c, d). Although there was no cytoplasmic TDP-43 in myoblasts, TDP-43 504 appeared in cytoplasmic puncta in differentiating myotubes at D8 (Supplementary Fig. 5d), in 505 agreement with the previous study of Vogler and collaborators showing cytoplasmic 506 translocation of TDP-43 into RNA myogranules at this stage [81]. Together, our data confirm 507 changes in the subcellular localization of both TDP-43 and FUS along myogenesis, suggesting 508 their involvement in the regulation of gene expression programs along muscle differentiation.

509 TDP-43 or FUS deficiency curtails anaerobic glucose metabolism and induces pro-510 atrophic pathways

Myogenesis poses a metabolic challenge for cells as the reliance on different metabolic
pathways changes throughout the differentiation process to meet specific energy demands.
Moreover, disturbances in energy metabolism have been repeatedly associated with the

514 pathogenesis of ALS [91] and TDP-43 is a recognized regulator of skeletal muscle glucose 515 homeostasis [9, 75]. Thus, we first investigated the extent of the metabolic reconfigurations that 516 occur in control myoblasts during myogenesis (Supplementary Fig. 6). Metabolic flux analysis 517 confirmed that glycolysis was the predominant metabolic pathway to produce basal ATP for 518 myoblast proliferation, as indicated by higher extracellular acidification rates (ECAR) and 519 lower oxygen consumption rates (OCR) (Supplementary Fig. 6a-c). However, differentiating 520 and fusing myocytes as well as early myotubes switch their metabolism from glycolytic ATP 521 production to oxidative phosphorylation (Supplementary Fig. 6a-c). To assess the impact of 522 changes in metabolism, we treated proliferating myoblasts with 2-deoxyglucose (2-DG) to 523 reduce glycolysis-dependent ATP production. 2-DG induced a myogenesis blockade (Fig. 3a, 524 b), and decreased MYOD and MYOG levels followed by an increase in Atrogin-1 (Fig. 3 c-e).

525 Thus, we sought to investigate the metabolic effects of TDP-43/FUS knockdown on human 526 myoblasts, and whether the myogenic defects induced by loss of TDP-43/FUS may be 527 explained by glucose metabolism abnormalities. We found that basal glycolysis, maximal glycolytic capacity and glycolysis-derived ATP production, as calculated from ECAR values, 528 529 were consistently repressed after silencing TDP-43 or FUS (Fig. 3f). The knockdown of FUS, 530 and to a lesser extent of TDP-43, also affected mitochondrial respiration, as observed by a 531 reduction in basal OCR and mitochondrial-derived ATP production (Fig. 3g, h). However, the 532 maximal and spare respiratory capacity was found increased in TDP-43-silenced myoblasts (Fig. 3g), although this could be due to the higher number of mitochondria (Supplementary Fig. 533 534 4 a, b) that would respond under experimental conditions to the uncoupler of mitochondrial 535 oxidative phosphorylation FCCP.

These findings suggest that both TDP-43 and FUS silencing resulted in overall abnormalities in energy metabolism during myogenic differentiation. However, the impact was particularly pronounced in the glycolytic flux, linking disturbances in glycolytic metabolism with myogenic deficiencies in silenced myoblasts. Thus, collectively, these data suggest that glucose energy homeostasis may be a key factor underlying the effects that TDP-43 or FUS silencing have on muscle formation, essentially by impairing myogenesis but also by inducing pro-atrophic programs.

TDP-43 and FUS silencing dysregulates FOXO transcription factors and related signalling pathways

545 Since TDP-43 and FUS LoF are associated with extensive changes in gene expression and 546 splicing events [26], we employed RNA sequencing to define the global gene expression 547 profiles of silenced myoblasts in an attempt to gain insights into the pathways and processes

548 modulated by TDP-43 and FUS that might be relevant for muscle homeostasis. Overall, 1,468 549 and 357 genes were upregulated (\log_2 fold change ≥ 1 , false discovery rate [FDR] ≤ 0.001), 550 whereas 1,597 and 883 genes were downregulated (log₂ fold change \leq -1, FDR \leq 0.001) 551 (Supplementary Table 2) in shTDP-43 and shFUS cells, respectively. Almost two-thirds of the 552 differentially expressed genes in shFUS myoblasts overlapped those in shTDP-43 myoblasts (62%; 767 out of 1,240); representation factor: 4.03; p<0.001) (Fig. 4a), of which 95% (730 out 553 554 of 767) had the same pattern of dysregulation and similar degree of fold change (Fig. 4b). To 555 characterise the functional effects of TDP-43 or FUS scarcity in myoblasts, we carried out GSEA using the Hallmark Pathway. Interestingly, we found consistent gene sets enrichment in 556 557 myogenesis with negative gene regulation across TDP-43 and FUS-silenced myoblasts (Fig. 4c; 558 Supplementary Table 3). Enrichment using the GO biological process, GO molecular function 559 and KEGG pathways with GSEA confirmed the significant enrichment with negative gene 560 regulation of sarcomere organisation, muscle organ development, striated muscle contraction 561 and striated muscle cell differentiation among others (Supplementary Fig. 7a-c and 562 Supplementary Table 3). Furthermore, the Hallmark GSEA also revealed significant enrichment 563 with negative gene regulation of Myc-related targets and MTORC1 signalling gene sets (Fig. 564 4c), which can contribute to the dysregulation of the fine tuning between metabolism and cell 565 differentiation during myogenesis [63]. To delineate the transcriptional regulators controlling 566 these altered gene programs of muscle development/differentiation, we performed a motif-567 centric transcription factors (TF) activity analysis by ISMARA (Integrated System for Motif 568 Activity Response Analysis [1]) to characterise the TFs whose motifs' activities most 569 significantly change by TDP-43 or FUS knockdown. This analysis identified a deactivation 570 across shTDP-43 and shFUS-silenced myoblasts of transcriptional regulators related to the 571 functional programs identified by GSEA, myogenesis and muscle contraction, including 572 MEF2A, MEF2C, MEF2D, MYOD1 and MYOG (Fig. 4d and Supplementary Table 4); these 573 last two are in agreement with the substantial decreases in their protein levels (Fig. 2b). Thus, 574 our robust transcriptomic analysis reflects the molecular and functional experimental 575 phenotypes, thus offering reliability to any mechanistic predictions obtained from this dataset. 576 In this line, we sought candidates among the top transcriptional regulators (identified by 577 ISMARA) with consistent activation across shTDP-43 and shFUS-silenced myoblasts for 578 abnormal transcriptional activity related to the associated phenotypes (Fig. 4d and 579 Supplementary Table 4). The enrichment of FOXO1/FOXO6 TF motifs was expected because 580 myogenesis and muscle growth require the repression of muscle atrophy programs regulated by 581 FOXO1 [22, 68], and because transcriptional activity of FOXO1 can be pharmacologically 582 modulated [43]. Moreover, FOXO TFs are also implicated in cell metabolism, and they 583 integrate insulin signalling with glucose and lipid metabolism to orchestrate cellular processes 584 such as cell differentiation and autophagy [31, 85]. Thus, we next sought to explore the link

between the family of FOXO TFs (focusing on FOXO1 and FOXO3 due to their involvement in
the skeletal muscle) and the two main functional phenotypes observed after TDP-43 and FUS
silencing: the defects in myogenic differentiation, including upregulation of pro-atrophic
pathways, and metabolism.

589 FOXO1 is particularly identified as key negative regulator of muscle growth, metabolism, and 590 differentiation but is crucial for myoblast fusion [4, 46, 85]. Specifically, FOXO1 activation in 591 muscle cells upregulates Atrogin-1 and MURF1 genes and downregulates MYOD expression 592 [27, 39, 40], which mimics the effects of TDP-43 or FUS knockdown in myoblasts (Fig. 2b, e). 593 Since transcriptional activation of FOXO requires its translocation to the nucleus, we analysed 594 and quantified the nuclear localization of FOXO proteins across the myogenic process as well 595 as after TDP-43 or FUS silencing in myoblasts. In control conditions, nuclear expression of 596 FOXO1 in proliferative myoblasts was low, but it increased during the fusion events, with a 597 concomitant decrease in cytoplasmic expression in early myotubes, which suggests 598 translocation to the nucleus (Supplementary Fig. 8a). This result agrees with previous findings 599 showing that FOXO1 impedes myogenic re-activation in myotubes [49]. However, nuclear 600 FOXO1 became abnormally elevated in shTDP-43 and shFUS proliferating myoblasts, 601 indicated by a rise in the percentage of cells with FOXO1-positive nuclei compared to shRNA 602 cells (3.19-fold and 12.14-fold change, respectively) (Fig. 4e)., corroborating the activation of 603 the FOXO1 TF motif inferred by ISMARA analysis. To investigate whether glycolytic 604 repression activates FOXO1, we treated control myoblasts with 2-DG. This resulted in an 605 increase in the number of cells with nuclear FOXO1 (8.26-fold), comparable to the effect 606 observed upon FUS silencing (Supplementary Fig. 8b and Fig. 4e). Thus, the 2-DG-induced 607 changes in MYOD and Atrogin-1 (Fig. 3d, e) are likely mediated by FOXO1 activation, and 608 equally, FOXO1 activation after TDP-43/FUS silencing can be attributed to glycolytic 609 repression.

In contrast to FOXO1, FOXO3, crucial for proliferation, exhibited a predominantly nuclear
localization in control myoblasts (Supplementary Fig. 8a) as previously described in murine
myoblasts [22], with decreased levels during differentiation (Supplementary Fig. 8a). However,
levels of nuclear FOXO3 were also increased in shTDP-43 cells (2.86-fold) and in shFUS cells
(2.32-fold) when compared to shRNA-proliferating myoblasts (Supplementary Fig. 9a).

Together, our data point to an early activation of FOXO1 activity in myoblasts with TDP-43 or
FUS silencing, most likely related to defects in glucose utilization pathways with deleterious
consequences for myogenesis.

618 FOXO1 inhibition rescues myogenic and metabolic defects in ALS myoblasts

619 We next tested whether FOXO1 inhibition rescues the underlying effects of TDP-43/FUS 620 deficiency in myoblasts. Targeting FOXO1 mRNA with shRNAs (shFOXO) reduced FOXO1 621 levels in TDP-43 and FUS-knockdown myoblasts (Supplementary Fig. 10), and improved their 622 myogenic capacity as evidenced by increased differentiation and fusion indices (Fig. 5a). To 623 elucidate further the role of FOXO1, we employed AS1842856 (iFOXO1), a quinolone-derived 624 molecule that selectively inhibits FOXO1 transactivation. With 100-fold greater potency in 625 targeting FOXO1 DNA interaction than other FOXO factors, iFOXO1 effectively disrupted 626 FOXO1-mediated transactivation [43]. Strikingly, iFOXO1 treatment (33 nM) significantly 627 improved the myogenic capacity of TDP-43-silenced myoblasts. This was evidenced by a 628 increase in the differentiation index (4.08-fold) and in the fusion index (6.59-fold) in shTDP-43 629 myoblasts. Furthermore, iFOXO1 treatment activated myogenesis in shFUS-silenced myoblasts 630 (Fig. 5b). These effects were similar to those observed in shFOXO1 knockdown (Fig. 5b). In 631 addition, iFOXO1 treatment led to a significant increase in MYOD1 protein levels in shTDP-43 632 myoblasts (2.01-fold) and in shFUS myoblasts (3.02-fold) (Fig. 5c). Finally, as muscle 633 dysfunction of silenced myoblasts was accompanied by altered energy metabolism (Fig. 3f), we 634 also analysed the effect of FOXO1 inhibition in this context. Indeed, iFOXO1 rescued the 635 glycolytic flux impairment caused by TDP-43 or FUS silencing, resulting in a significant 636 increase in basal glycolysis (1.61-fold and 1.67-fold, respectively) (Fig. 5d). In addition, 637 iFOXO1 treatment also improved the mitochondrial ATP production (Fig. 5d), thus, exerting 638 thorough benefits in the pathways of energy production in the absence of TDP-43 or FUS.

639 We next analysed FOXO expression in ALS patient-derived myoblasts by immunofluorescence. 640 Nuclear FOXO1 levels were significantly elevated in ALS compared to CTRL myoblasts, 641 evidenced by an increase in the percentage of cells with FOXO1-positive nuclei (2.85-fold) 642 (Fig. 6a). We also observed a slight increase in the levels of nuclear FOXO3 (Supplementary 643 Fig. 9b). Hence, ALS and TDP-43 or FUS silenced myoblasts share the same nuclear 644 distribution of FOXO1/3 (Fig. 4e). Additionally, FOXO1 protein was also found to be increased 645 in the cytoplasm of ALS patient-derived myoblasts compared to controls (3.26-fold) (Fig. 6a). 646 iFOXO1 treatment specifically improved myogenic capacity in ALS myoblasts, as evidenced by 647 the enhanced myogenic differentiation and fusion indices in ALS myoblasts. Compared to 648 control myoblasts, ALS myoblasts exhibited a marked increase in the differentiation index (3.32-fold) and fusion index (3.47-fold). Notably, 7 out of 8 ALS myoblasts responded 649 650 positively to the treatment (Fig. 6b). Conversely, CTRL myoblasts displayed a weaker increase 651 in differentiation (1.61-fold) and fusion (1.59-fold) indices. The treatment also boosted 652 glycolytic flux in the sALS myoblasts (Fig. 6c). Together these data suggest that FOXO1 653 inhibition improves myogenic and metabolic outcomes in ALS muscle cells.

654 To determine whether these findings extended to other neurogenic atrophies, we studied 655 primary myoblasts from different disorders including other MN diseases, such as SMA3 or 656 SBMA. As an example of neuropathy, we also analysed primary myoblasts from a patient with 657 Charcot-Marie-Tooth type 4 (CMT4; recessive and demyelinating disease) (Supplementary Fig. 658 11). We first examined the proliferation rates of these samples, which, collectively, were not affected in the disease group. However, at the individual level, we observed an apparent 659 660 decrease in SMA3 sample (Supplementary Fig. 11a). We then compared the total protein levels 661 of TDP-43 and FUS by immunoblotting, finding some variability, but no general pattern of 662 change. However, SMA3 and SBMA myoblasts displayed FUS downregulation, whereas 663 CMT4 myoblasts showed TDP-43 upregulation (Supplementary Fig. 11b). Expression of 664 FOXO1 in these cells was similar to CTRL myoblasts, with a low nuclear percentage (<15%; 665 Supplementary Fig. 11c), suggesting a specific pathological mechanism for ALS (65%; Fig. 6a). 666 Finally, differentiation assays did not suggest any appreciable impairment when comparing this 667 group of diseases with the CTRL group. However, SMA3 and, particularly, CMT4, as well as 668 the aged CTRL (CTRL_6, 7 and 8) myoblasts, displayed a low myogenic capacity 669 (Supplementary Fig. 11d, e). Interestingly, FOXO1 inhibition with iFOXO1 rescued the 670 myogenic deficit only in SMA3 (Supplementary Fig. 11f).

671 Finally, we studied myoblasts from patients with muscular disorders characterized by protein 672 aggregates resembling those found in ALS, such as a sporadic Inclusion Body Myositis (IBM) 673 and a vacuolar myopathy related to Valosin-Containing Protein (VCP) mutations (devoid of 674 ALS/FTD manifestations). While FOXO1 inhibition enhanced the myogenic program in both ALS and VCP-myopathy myoblasts (Supplementary Fig. 11f), particularly in VCP-myopathy 675 676 with a 2.75-fold increase in the differentiation index, we did not observe mislocalization of 677 FOXO1 to the nucleus (Supplementary Fig. 11c) or a negative impact on myogenesis 678 (Supplementary Fig. 11d, e).

These results suggest that a marked increase of nuclear FOXO1 in myoblasts represents a specific ALS signature, not observed in other MN diseases such as SMA and SBMA, or neuropathies like CMT4. On the other hand, FOXO1 inhibition improved differentiation and fusion indices in diseases exhibiting FUS downregulation, including SMA type 3, SBMA, and VCP disease (Supplementary Fig. 11b). In contrast, no such rescue effect was observed in CMT4 myoblasts, which correlated with unchanged FUS expression levels (Supplementary Fig. 11b).

686 Inhibition of FOXO1 improves neuromuscular function and lifespan in Drosophila models

687 Our *in vitro* findings highlight the dysregulation of FOXO1 as a shared feature of ALS patientderived myoblasts and synthetic TDP-43 and FUS deficient myoblasts. Notably, FOXO1 688 689 inhibition improved myogenic performance and metabolic fitness in these cells. Based on these 690 results, we aimed to assess the effects of targeting FOXO factors on muscle function in vivo, 691 generating different Drosophila melanogaster models with conditional silencing of either Cabeza (caz) or TBPH genes (human FUS or TARDBP orthologs, respectively) by dsRNA 692 693 specifically in muscle tissue (Fig. 7a and Supplementary Fig. 12a). caz and TBPH knockdown 694 were conditioned to the expression of the Myocyte enhancer factor 2 (DmeI/Mef2) gene, a TF 695 whose expression is mostly restricted to both muscle differentiated and muscle precursor cells 696 and which is essential for myogenesis [5, 56]. With this approach, we silenced *caz* or *TBPH* 697 specifically in the skeletal muscle of Drosophila flies using different long-hairpin iRNA 698 libraries (Supplementary Fig. 12a). Each generated fly model silenced a single and different 699 locus of *caz* or *TBPH* genes. Respectively, *caz* or *TBPH* gene expression is significantly 700 reduced in iCaz or iTBPH models (Supplementary Fig. 12b). Notably, fly models from KK libraries (iCaz and iTBPH^{pkk(108354)}) silenced more efficiently *caz* or *TBPH* (by ca 50%) 701 (Supplementary Fig. 12b). Moreover, the iTBPH^{pkk(108354)} fly model showed not only a 702 703 prominent TBPH expression decrease but also a subsequent and significant reduction of caz 704 gene expression (Supplementary Fig. 12b), as we showed for FUS in TDP-43-silenced 705 myoblasts (Fig. 2b). This result confirms the functional co-regulation between TBPH and caz 706 gene expression [82], as it also occurs in human orthologs TDP-43 and FUS [56].

707 While *caz*-silenced (*icaz*) flies and two different lines of *TBPH*-silencing (iTBPH^{attp40} and iTBPH^{p(GD6943)}) were viable, the third TBPH-silenced line (iTBPH^{pkk(108354)}) exhibited lethality in 708 newly metamorphosed adults (pharate), not even being able to hatch out of its pupa (Fig. 7a). 709 Adult iTBPH^{attp40} and iCaz flies exhibited the most pronounced motor phenotypes, detectable as 710 711 early as 10 days old. This was evidenced by a climbing ability of only 30-40% of flies in the locomotor activity test. (Fig. 7b). However, adult iTBPH^{p(GD6943)} flies displayed such phenotype 712 713 at 15-day old (Fig. 7b). Finally, to complete the phenotypical-functional characterization of the 714 models, we performed longevity assays, demonstrating a significantly decreased lifespan across 715 iCaz and iTBPH fly models (Fig. 7c).

716 *Drosophila* has only one ortholog for mammalian FOXO transcription factors, named *foxo*. 717 Although the affinity of the AS1842856 compound (iFOXO1) for *Drosophila*'s *foxo* has never 718 been tested, as FOXO binding sites for this compound are well conserved (Supplementary Fig. 719 12c), we first tested its efficacy in our models. After verifying that iFOXO1 (30μ M) showed no 720 toxicity on motor function and lifespan in control flies (Supplementary Fig. 12d, e), we applied 721 iFOXO1 treatment in *icaz* and *iTBPH* flies. Strikingly, *foxo* inhibition resulted notably 722 improved muscle function, as evidenced by a significant increase in climbing activity. This

effect was more pronounced in iTBPH flies (approximately 80% climbed) compared to iCaz
flies (approximately 60% climbed) (Fig. 7d and Supplementary Videos 1-7). Furthermore,
treated flies significantly increased their survival, particularly for the iCaz and iTBPH^{attp40} fly
lines (Fig. 7e-g).

As mentioned above, iTBPH^{pkk(108354)} flies displayed adult pharate lethality, presumably due to 727 728 insufficient muscle strength to exit the pupa once metamorphosis is complete. Noteworthily, iFOXO1 treatment significantly reduced pharate lethality in iTBPH^{pkk(108354)} flies. This was 729 evidenced by a substantial increase in survival rate, from 2% to 20%, at the pharate pupal stage 730 (Fig. 7h). Indeed, histopathological analysis revealed a dramatic denervation of iTBPH^{pkk(108254)} 731 732 thoracic muscles, as observed by both a decrease in the number of HRP-positive neuronal 733 branches (-7.14-fold) and in the size of neuromuscular synapses (-1.4-fold) (bruchpilot+, a 734 marker of mature and functional synapses in Drosophila) (Fig. 7i-k), confirming a denervation phenotype in these TBPH muscle-silenced flies. Surprisingly, the treatment with iFOXO1 735 736 induced a significant increase in the size of the neuromuscular synapses of the remaining MNs 737 (1.25-fold) (Fig. 7i, j), correlating with the survival increase. However, the treatment was unable to show signs of improvement in the number of terminal MN innervating the muscle (Fig. 7k). 738

Together, the combined data obtained from the *in vivo* models and *in vitro* experiments suggest
a hopeful prospect for using FOXO1 inhibition to restore muscle homeostasis challenged by
TDP-43 or FUS LoF, suggesting a potential benefit to reduce muscle wasting in ALS patients.
Providing this initial evidence, these data also promote that therapies aimed at preserving
muscle function could potentially offer protection to MNs.

744 **DISCUSSION**

745 ALS is a complex and devastating disease that affects MNs and involves a multitude of altered 746 processes and pathways, making the development of effective therapeutic strategies challenging 747 [91]. Recent research has highlighted the implication of skeletal muscle in the disease, not only 748 as a consequence but also as a potential contributor to the origin and spread of the pathology 749 [17, 55, 70]. In this work, we have sought to provide further evidence of the molecular bases 750 underlying the intrinsic muscle abnormalities of ALS to pinpoint mechanisms that can be 751 targeted to improve muscle health and, ultimately, slow down the disease pathology. In this 752 sense, we demonstrate that myogenesis, glucose metabolism and pro-atrophic pathways are 753 affected in ALS muscle progenitor cells independently of the MN input, being the role of TDP-754 43 and FUS essential in these processes. Aberrant hyperactivation of FOXO transcription factors was identified as an underlying mechanism, evidenced by FOXO1 nuclear translocation 755 756 and FOXO1 motif activity upregulation. We evidence that FOXO1 activity can be 757 pharmacologically modulated to recover muscle homeostasis in ALS cells and to improve the 758 neuromuscular function in ALS Drosophila models with muscle-specific TDP-43 and FUS 759 silencing.

760 To decipher the molecular basis of muscle contribution to ALS pathology, we have focused our 761 study on the capacity of muscle resident precursor cells (the myoblasts) to fulfil their 762 compromise for muscle regeneration. The skeletal muscle has an extraordinary regenerative 763 capacity to recover from severe damage and even atrophy under physiological conditions [59], 764 by activating the myogenic program in muscle progenitor cells. However, ALS muscle atrophy 765 is irreversible and follows a progressive pattern that determines the disease severity, being 766 disabling and fatal for the patients [38]. A plausible hypothesis is that the regenerative capacity 767 of ALS muscle is impaired, to the point of not compensating for denervation-induced atrophy. 768 According to this hypothesis, we found defects in the process of muscle regeneration in almost 769 all ALS samples, in agreement with previous studies [57, 69], which were further accompanied 770 by changes in the levels of the myogenic regulatory factors (MRF) MYOD and MYOG. 771 Initially, we elucidated whether two of the most implicated factors in ALS pathology, TDP-43 772 and FUS, might be involved in such myogenic defects. Indeed, we identified a faint presence of 773 cytoplasmic TDP-43 granules as early as day 3 after human myocyte fusion in human control 774 myotubes. Accordingly, a previous study reported that TDP-43 forms physiological cytoplasm 775 granules in murine C2C12 myotubes at late stages of differentiation, which are critical for 776 regulating sarcomeric protein translation and myotube maturation in mice [81] cytoplasmic 777 TDP-43 protein granules in myoblasts from either ALS patients or control subjects. This suggests that during the early stages of myogenesis, cytoplasmic TDP-43 may play a minimal 778

779 role. However, TDP-43 total levels appeared decreased in ALS myoblasts, suggesting that 780 nuclear TDP-43 may also play a significant role in the early stages of differentiation by 781 regulating myogenic gene programs. This hypothesis can also be extended to FUS, as ALS 782 myoblasts demonstrate decreased FUS expression, which is normally localized primarily to the 783 nuclei of proliferating myoblasts but is absent from differentiated myotubes. Nonetheless, we 784 must consider some variability in myogenesis among ALS patients. For instance, in fALS2, the 785 only patient without differentiation problems presents a familial form with slower disease 786 progression. There is also more variability in healthy individuals, where we observed a clear 787 correlation with aging. As this correlation is lost in ALS, we anticipate that myogenic 788 impairments are genuinely associated with ALS pathology, thus, suggesting premature aging 789 [52]. Since we reported general decreased TDP-43 and FUS expression in the ALS samples, we 790 investigated the mechanisms and processes related to myogenesis impacted by TDP-43 or FUS 791 knockdown in proliferating myoblasts.

792 TDP-43 or FUS knockdown was sufficient to replicate the myogenic defects observed in patients' cells. These results are in agreement with those achieved by the silencing of other 793 794 ALS-causative genes. For instance, OPTN silencing delayed muscle regeneration in mice and 795 impaired myogenic differentiation in C2C12 mouse myoblasts [72], and RNA-binding proteins 796 whose mutations cause ALS, such as hnRNPA1, hnRNPA2B1 or MATR3, control myogenic 797 cell fate transitions during differentiation by regulating the expression and alternative splicing 798 of muscle-related genes [2, 32, 50, 83]. Hence, the diversity of ALS-associated genes 799 influencing myogenic cell fate transitions highlights the potential for various triggers to cause myogenic alterations in ALS. While our knockdown model represents a simplified approach to 800 801 the complex TDP-43 proteinopathy, it is important to note that the loss of TDP-43 function, 802 particularly its role in cryptic splicing repression, is thought to precede the formation of TDP-803 43-positive inclusions [8]. Therefore, our silencing approach mimics an early stage of the 804 disease, making it valuable for studying the underlying pathogenic mechanisms.

805 The myogenic process requires a series of consecutive steps that demand a fine-tuned regulation 806 of metabolism and a flexible use of energy resources [15, 50], as we confirmed in the human 807 immortalised myoblast cell line used in this work. In the earliest stages of myoblast 808 differentiation, the reliance on glycolysis is critical, as we demonstrated after inhibiting 809 myoblasts with 2-DG resulting in myogenic repression, whereas in later stages of myotube 810 maturation, energy is mostly supplied by mitochondrial oxidative phosphorylation [50, 79]. 811 Indeed, glycolysis not only provides a rapid source of energy and carbon sources to underpin 812 myoblast growth but also acts as an epigenetic regulator of myoblast proliferation through 813 modulation of histone acetylation [87]. As alterations in glucose metabolism are major within

814 the overall metabolic disturbances of ALS [3, 91], it is plausible to anticipate that these may 815 impinge on the myogenic process and, in turn, affect muscle function. Interestingly, the 816 knockdown of TDP-43 or FUS in myoblasts dramatically reduced the ability to use glucose, and 817 pro-atrophic pathways became consequently activated. These results fit previous studies 818 describing the role of TDP-43 in the regulation of skeletal muscle glucose homeostasis, which 819 involves glucose uptake facilitation mediated by the interaction between TBC1D1 and the 820 glucose transporter GLUT4 [9, 75]. This highlights the important role that TDP-43 and FUS 821 play in glucose oxidation pathways to regulate muscle function, avoiding the induction of pro-822 atrophic programs.

823 Through the analysis for enriched TF motifs from RNA-seq data, specific genes related to 824 muscle differentiation and growth appeared to be deactivated, confirming the intrinsic muscle 825 dysfunction. Among these factors, we found MYOD and MYOG (essential for myogenesis), 826 which we confirmed to be downregulated in ALS samples, and MEF2 TF, whose inactivation 827 induces skeletal muscle atrophy [45, 71]. Regarding the activated genes, besides FOXO1, TP53 828 appeared as another plausible candidate to be further studied, as its upregulation also suppresses 829 cell growth, specifically by repressing MYOG in the skeletal muscle, leading to the inhibition of 830 late differentiation markers [86]. As such, further analysis of these factors should be done to 831 decipher their impact in ALS pathophysiology. However, based on the TF and our expertise in 832 the molecular regulation of muscle stem cells [19], we uncovered dysregulation of FOXO 833 transcription factors as a converging molecular mechanism linking the impaired myogenesis 834 and the altered glycolysis in the absence of TDP-43 and FUS. Although FOXO1 must be 835 excluded from the nucleus becoming inactive in myoblasts during myogenesis [22], we found FOXO1 expressed in the nuclei of all ALS patient myoblasts as well as in TDP-43- or FUS-836 837 silenced myoblasts, suggesting this change as a consistent pathogenic feature in ALS muscle. 838 Indeed, such activation of nuclear FOXO1 did not appear in the other diseases, such as SMA3, 839 SBMA, CMT4, IBM, or VCP. FOXO1 induction may occur as a cellular response to the 840 inability to obtain energy from glucose oxidation. Although FOXO1 inhibits glycolysis per se 841 by regulating PDK4 expression [16, 20, 58], and thus controlling the activity of the main 842 glycolysis-limiting enzyme, pyruvate dehydrogenase (PDH), the fact that FOXO1 was activated 843 after repressing glycolysis with 2-DG or after TDP-43 or FUS silencing could be explained by 844 the role of FOXO1 in nutrient switching during glucose shortage [66]. Indeed, our results 845 indicate that FOXO1 inhibition facilitates glucose metabolism, shown as an increased lactate 846 production and basal mitochondrial respiration. On the other hand, TDP-43 directly represses 847 nuclear FOXO1 transactivation [88]; therefore, a dysfunction of TDP-43 would release such 848 repression leading to an increase in FOXO1 activity and, consequently, to the inhibition of glycolysis. Together, our data point to abnormal FOXO1 activation in ALS muscle due to TDP-849

43 or FUS knockdown, which ultimately impairs the muscle regenerative capacity. This FOXO1 overactivation may occur due to the release of FOXO1 repression in the absence of TDP-43, secondary to alterations in glucose metabolism, or both. Actually, the overactivation of FOXO1 in ALS muscle could explain the switch from glucose to muscle lipid utilisation described at early stages in the SOD1-G93A mouse, prior to symptoms onset and MN loss [12, 51].

856 Importantly, there are several studies that have underscored the critical role of FOXO TF in 857 muscle atrophy [68]. Conversely, myostatin treatment, known for its negative regulation of 858 muscle growth, reverses the IGF-1/PI3K/AKT hypertrophy pathway by inhibiting AKT 859 phosphorylation, thereby elevating active FOXO1 levels and promoting the expression of 860 atrophy-related genes [39]. Furthermore, FOXO1's negative regulatory influence on skeletal 861 muscle mass and type I fibre gene expression has been proposed, potentially contributing to 862 sarcopenia, obesity, and diabetes in humans [25]. Additionally, FOXO3 activation, which leads 863 to significant muscle atrophy via the transcription of atrophy-related genes, including crucial 864 ubiquitin ligases [89], emerges as a potential therapeutic target for muscle wasting disorders and 865 degenerative diseases involving autophagy [35], further supported by research indicating 866 enhanced FOXO-dependent muscle mass loss associated with a decline in PGC1-alpha during 867 atrophy [67]. Finally, Nakashima and Yakabe stated that when AMPK signalling pathway is 868 enhanced by AICAR in C2C12 myotubes, it promotes myofibrillar protein degradation through 869 increased expression of atrogin-1 and MuRF1, facilitated by elevated levels of FOXO TF in 870 skeletal muscles [44]. Together, this data moved us to consider FOXO1 as a plausible target in 871 which to intervene.

872 Considering our results, FOXO1 inhibitors may have the potential to treat TDP-43 or FUS LoF-873 induced muscle alterations, such as those in ALS. Indeed, FOXO inhibition induces overall 874 locomotor and survival benefits in fruit flies with specific muscle knockdown of TBPH and caz. 875 Actually, the four different Drosophila ALS models used in this study reproduce some ALS 876 outcomes, such as shortened lifespan and impaired neuromuscular function, as described for 877 TDP-43 knockdown in Drosophila [76]. One of the TBPH knockdown models exhibited a 878 pharate lethality phenotype, likely resulting from the extensive denervation of thoracic muscles 879 caused by TBPH knockdown, which in turn led to inadequate tractor capacity for exiting the 880 pupa. Interestingly, this model displayed greater phenotypic severity compared to the others, 881 potentially due to cumulative effects resulting from secondary *caz* dysregulation. The pharate 882 lethality in this model was rescued by FOXO1 inhibition, which likely improved the 883 neuromuscular synaptic contacts, favouring the subsequent pupal period eclosion. These 884 findings support the recent theory of non-cell autonomous mechanisms of neurodegeneration in

ALS [21] that implicate distal axonopathy as the initiating event in the disease [41], and provide compelling evidence that treatments aimed at restoring muscle function can alleviate MN neurodegeneration. However, it should be noted that *Drosophila* has only one *foxo* gene that performs the functions of all members of the human FOXO family, and the beneficial effects of the FOXO inhibitor treatment may be partially attributed to FOXO3 inhibition, which may also contribute to myoblast differentiation [74].

891 Overall, the restoration of the myogenic process being concomitant to glycolytic normalisation 892 supports that metabolic defects are linked to the myogenic phenotypes of TARDBP and FUS 893 knockdown cells. FOXO1 plays a crucial role in the interplay between metabolism and disease, 894 as it controls many of the physiological responses to metabolic stimuli, including those 895 mediated by insulin signalling [31]. Therefore, inhibiting FOXO1 could potentially counteract 896 the key functional consequences of TDP-43 or FUS loss-of-function, specifically in ALS 897 muscle cells. Additionally, recent studies have proposed FOXO transcription factors as 898 promising therapeutic targets for neurodegenerative diseases [6, 48]. Indeed, we show the 899 recovery of muscle differentiation through FOXO1 inhibition in other MN diseases such as 900 SMA3 and SBMA. Thus, highlighting this mechanism and downstream targets could encourage 901 the development of new therapeutic approaches for ALS that target skeletal muscle.

902

903 ACKNOWLEDGMENTS

The authors thank Dr. Vincent Mouly and the Platform for Immortalization of Human Cells (Myology Institute) for the human immortalised 8220 cell line, and Stéphane Vasseur from the MYOBANK-AFM (Myology Institute) for the human CMT4 myoblasts. We also thank Dr. Francesco P. Marchese from the Genomics Unit Platform at University of Navarra & Centre for Applied Medical Research (CIMA) for expertise and assistance in NGS. We want to dedicate this work specially to all ALS patients and their families.

910 FUNDING

911 This research was supported by the Biodonostia Health Research Institute (Biodonostia HRI) 912 and CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB06/05/1126, Group 913 609), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea -914 European Regional Development Fund. This work was funded by Instituto de Salud Carlos III 915 (ISCIII) and co-funded by the European Union (projects P18/01066, PI19/00175, PI21/00153, 916 PI22/00433); by CIBERNED (CIBER de Enfermedades Neurodegenerativas, project PI2020/08-917 1); by the Department of Education of the Basque Country through the IKUR strategy 918 (NEURODEGENPROT); Diputación Foral de Gipuzkoa (projects 2020-CIEN-000057-01, 919 2021-CIEN-000020-01); by EiTB Maratoia (project BIO17/ND/023/BD); and by Osasun Saila, 920 Eusko Jaurlaritzako (projects 2015111122, 2017222027, 2018111042, 2019222020, 921 2020111032, 2020333043, 2021333050). MZuf, OP-M, MG-A, AJ, AE, JO and UF-P were 922 supported by the Department of Education of the Basque Country (PhD fellowships 923 PRE 2015 1 0023, PRE 2019 1 0339, PRE 2020 1 0122, PRE_2020_1_0191, 924 PRE 2020 1 0119, PRE 2018 1 0095, PRE 2018 1 0253); MM-O by Basque Country 925 University (UPV/EHU) fellowship (PIF18/317); LB by the Spanish National Plan for Scientific 926 and Technical Research and Innovation -Ramon y Cajal- (RYC2018-024397-I) and 927 IKERBASQUE (RF/2019/001) research programs; GG by Juan de la Cierva-Incorporación 928 (ISCIII, IJC2019-039965-I) and IKERBASQUE (RF/2023/010) research programs; FG-B by 929 Roche Stop Fuga de cerebros (BIO19/ROCHE/017/BD) and IKERBASQUE (PP/2022/003) 930 research programs; and SA-M by Gipuzkoa Fellow of Talent Attraction and Retention (2019-931 FELL-000010-01, 2020-FELL-000016-02-01, 2021-FELL-000013-02-01).

932 Compliance with ethical standards

Conflict of interest SD is a named inventor on patents related to neurological disorders. MZuf,
ALM, GG, FGB and SAM are co-inventors of patent PCT/EP2021/064274 and therefore
entitled to a share of royalties. MZuf, LB, ALM, GGL, FGB and SAM also have ownership in
Miaker Developments S.L., which is the licensee of that patent related to the research being

- 937 reported. The terms of this arrangement have been reviewed and approved by the University of
- 938 the Basque Country and Biogipuzkoa Health Research Institute/BIOEF (representing the
- 939 Basque public administration), as co-owners of the patent.
- 940 **Ethics approval and consent to participate** This study was approved by the Clinical Research
- 941 Ethics Committees of the Basque Country and Donostia University Hospital (codes: ALM-
- 942 EMP-2015-01, PI2016075, PI2019198) (Spain). Written informed consent was obtained from
- all the subjects included in the study.
- 944 **Consent for publication** All authors consented to publication of this paper.

945

946 **REFERENCES**

- Balwierz PJ, Pachkov M, Arnold P, Gruber AJ, Zavolan M, Van Nimwegen E (2014)
 ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs.
 Genome Res 24:869–884. doi: 10.1101/gr.169508.113
- Banerjee A, Vest KE, Pavlath GK, Corbett AH (2017) Nuclear poly(A) binding protein 1
 (PABPN1) and Matrin3 interact in muscle cells and regulate RNA processing. Nucleic
 Acids Res 45:10706–10725. doi: 10.1093/NAR/GKX786
- Blasco H, Lanznaster D, Veyrat-Durebex C, Hergesheimer R, Vourch P, Maillot F,
 Andres CR, Pradat PF, Corcia P (2020) Understanding and managing metabolic
 dysfunction in Amyotrophic Lateral Sclerosis. Expert Rev Neurother 20:907–919. doi:
 10.1080/14737175.2020.1788389
- 957 4. Bois PRJ, Grosveld GC (2003) FKHR (FOXO1a) is required for myotube fusion of
 958 primary mouse myoblasts. EMBO J 22:1147–1157. doi: 10.1093/EMBOJ/CDG116
- 959 5. Bour BA, O'Brien MA, Lockwood WL, Goldstein ES, Bodmer R, Taghert PH, Abmayr
 960 SM, Nguyen HT (1995) Drosophila MEF2, a transcription factor that is essential for
 961 myogenesis. Genes Dev 9:730–741. doi: 10.1101/gad.9.6.730
- 962 6. Calissi G, Lam EWF, Link W (2021) Therapeutic strategies targeting FOXO transcription
 963 factors. Nat Rev Drug Discov 20:21–38. doi: 10.1038/S41573-020-0088-2
- Candelise N, Caissutti D, Zenuni H, Nesci V, Scaricamazza S, Salvatori I, Spinello Z,
 Mattei V, Garofalo T, Ferri A, Valle C, Misasi R (2023) Different Chronic Stress
 Paradigms Converge on Endogenous TDP43 Cleavage and Aggregation. Mol Neurobiol
 60:6346–6361. doi: 10.1007/S12035-023-03455-Z
- Chang K, Ling JP, Redding-Ochoa J, An Y, Li L, Dean SA, Blanchard TG, Pylyukh T, Barrett A, Irwin KE, Moghekar A, Resnick SM, Wong PC, Troncoso JC (2023) Loss of TDP-43 splicing repression occurs early in the aging population and is associated with Alzheimer's disease neuropathologic changes and cognitive decline. Acta Neuropathol 147. doi: 10.1007/S00401-023-02653-2
- 973 9. Chiang P-M, Ling J, Jeong YH, Price DL, Aja SM, Wong PC (2010) Deletion of TDP-43
 974 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc
 975 Natl Acad Sci U S A 107:16320–4. doi: 10.1073/pnas.1002176107

- 976 10. Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, On
- Behalf of the Eurals Consortium (2009) Prognostic factors in ALS: A critical review.
 Amyotrophic Lateral Sclerosis 10:310–323. doi: 10.3109/17482960802566824
- Danielson E, Lee SH, Fox MA (2014) SynPAnal: software for rapid quantification of the
 density and intensity of protein puncta from fluorescence microscopy images of neurons.
 PLoS One 9. doi: 10.1371/JOURNAL.PONE.0115298
- Dobrowolny G, Lepore E, Martini M, Barberi L, Nunn A, Scicchitano BM, Musarò A
 (2018) Metabolic Changes Associated With Muscle Expression of SOD1G93A. Front
 Physiol 9:831. doi: 10.3389/fphys.2018.00831
- Dobrowolny G, Martini M, Scicchitano BM, Romanello V, Boncompagni S, Nicoletti C,
 Pietrangelo L, De Panfilis S, Catizone A, Bouchè M, Sandri M, Rudolf R, Protasi F,
 Musarò A (2018) Muscle Expression of SOD1G93A Triggers the Dismantlement of
 Neuromuscular Junction via PKC-Theta. Antioxid Redox Signal 28:1105–1119. doi:
 10.1089/ars.2017.7054
- 990 14. Ervilha Pereira P, Schuermans N, Meylemans A, LeBlanc P, Versluys L, Copley KE,
 991 Rubien JD, Altheimer C, Peetermans M, Debackere E, Vanakker O, Janssens S, Baets J,
 992 Verhoeven K, Lammens M, Symoens S, De Paepe B, Barmada SJ, Shorter J, De Bleecker
 993 JL, Bogaert E, Dermaut B (2023) C-terminal frameshift variant of TDP-43 with
 994 pronounced aggregation-propensity causes rimmed vacuole myopathy but not ALS/FTD.
 995 Acta Neuropathol 145:793–814. doi: 10.1007/S00401-023-02565-1
- Fortini P, Ferretti C, Iorio E, Cagnin M, Garribba L, Pietraforte D, Falchi M, Pascucci B,
 Baccarini S, Morani F, Phadngam S, De Luca G, Isidoro C, Dogliotti E (2016) The fine
 tuning of metabolism, autophagy and differentiation during in vitro myogenesis. Cell
 Death Dis 7. doi: 10.1038/CDDIS.2016.50
- 1000 16. Furuyama T, Kitayama K, Yamashita H, Mori N (2003) Forkhead transcription factor
 1001 FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during
 1002 energy deprivation. Biochem J 375:365–371. doi: 10.1042/BJ20030022
- 1003 17. Le Gall L, Duddy WJ, Martinat C, Mariot V, Connolly O, Milla V, Anakor E, Ouandaogo
 1004 ZG, Millecamps S, Lainé J, Vijayakumar UG, Knoblach S, Raoul C, Lucas O, Loeffler
 1005 JP, Bede P, Behin A, Blasco H, Bruneteau G, Del Mar Amador M, Devos D, Henriques
 1006 A, Hesters A, Lacomblez L, Laforet P, Langlet T, Leblanc P, Le Forestier N, Maisonobe
 1007 T, Meininger V, Robelin L, Salachas F, Stojkovic T, Querin G, Dumonceaux J, Butler
 1008 Browne G, González De Aguilar JL, Duguez S, Pradat PF (2022) Muscle cells of

1009		sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesicles. J Cachexia
1010		Sarcopenia Muscle 13:1385–1402. doi: 10.1002/JCSM.12945
1011	18.	Gallo V, Vanacore N, Bueno-de-Mesquita HB, Vermeulen R, Brayne C, Pearce N, Wark
1012		PA, Ward HA, Ferrari P, Jenab M, Andersen PM, Wennberg P, Wareham N, Katzke V,
1013		Kaaks R, Weiderpass E, Peeters PH, Mattiello A, Pala V, Barricante A, Chirlaque MD,
1014		Travier N, Travis RC, Sanchez MJ, Pessah-Rasmussen H, Petersson J, Tjønneland A,
1015		Tumino R, Quiros JR, Trichopoulou A, Kyrozis A, Oikonomidou D, Masala G, Sacerdote
1016		C, Arriola L, Boeing H, Vigl M, Claver-Chapelon F, Middleton L, Riboli E, Vineis P
1017		(2016) Physical activity and risk of Amyotrophic Lateral Sclerosis in a prospective cohort
1018		study. Eur J Epidemiol 31:255–266. doi: 10.1007/s10654-016-0119-9
1019	19.	García-Prat L, Perdiguero E, Alonso-Martín S, Dell'Orso S, Ravichandran S, Brooks SR,
1020		Juan AH, Campanario S, Jiang K, Hong X, Ortet L, Ruiz-Bonilla V, Flández M,
1021		Moiseeva V, Rebollo E, Jardí M, Sun HW, Musarò A, Sandri M, Sol A del, Sartorelli V,
1022		Muñoz-Cánoves P (2020) FoxO maintains a genuine muscle stem-cell quiescent state
1023		until geriatric age. Nat Cell Biol 22:1307–1318. doi: 10.1038/S41556-020-00593-7
1024	20.	Gross DN, Wan M, Birnbaum MJ (2009) The role of FOXO in the regulation of
1025		metabolism. Curr Diab Rep 9:208-14. doi: 10.1007/s11892-009-0034-5
1026	21.	Van Harten ACM, Phatnani H, Przedborski S (2021) Non-cell-autonomous pathogenic
1027		mechanisms in amyotrophic lateral sclerosis. Trends Neurosci 44:658-668. doi:
1028		10.1016/J.TINS.2021.04.008
1029	22.	Hribal ML, Nakae J, Kitamura T, Shutter JR, Accili D (2003) Regulation of insulin-like
1030		growth factor-dependent myoblast differentiation by foxo forkhead transcription factors.
1031		Journal of Cell Biology 162:535-541. doi: 10.1083/jcb.200212107
1032	23.	Jensen L, Jørgensen LH, Bech RD, Frandsen U, Schrøder HD (2016) Skeletal Muscle
1033		Remodelling as a Function of Disease Progression in Amyotrophic Lateral Sclerosis.
1034		Biomed Res Int 2016:1–12. doi: 10.1155/2016/5930621
1035	24.	Julian TH, Glascow N, Barry ADF, Moll T, Harvey C, Klimentidis YC, Newell M,
1036		Zhang S, Snyder MP, Cooper-Knock J, Shaw PJ (2021) Physical exercise is a risk factor
1037		for amyotrophic lateral sclerosis: Convergent evidence from Mendelian randomisation,
1038		transcriptomics and risk genotypes. EBioMedicine 68. doi:
1039		10.1016/J.EBIOM.2021.103397
1040	25.	Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, Mochida K, Hata T,
1041		Matsuda J, Aburatani H, Nishino I, Ezaki O (2004) Skeletal muscle FOXO1 (FKHR)

transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red
muscle) fiber genes, and impaired glycemic control. J Biol Chem 279:41114–41123. doi:
1044 10.1074/JBC.M400674200

1045 26. Kapeli K, Pratt GA, Vu AQ, Hutt KR, Martinez FJ, Sundararaman B, Batra R, Freese P, 1046 Lambert NJ, Huelga SC, Chun SJ, Liang TY, Chang J, Donohue JP, Shiue L, Zhang J, 1047 Zhu H, Cambi F, Kasarskis E, Hoon S, Ares M, Burge CB, Ravits J, Rigo F, Yeo GW 1048 (2016) Distinct and shared functions of ALS-associated proteins TDP-43, FUS and 1049 TAF15 revealed by multisystem analyses. Nat Commun 7:12143. doi: 1050 10.1038/ncomms12143

1051 27. Kitamura T, Kitamura YI, Funahashi Y, Shawber CJ, Castrillon DH, Kollipara R,
1052 DePinho RA, Kitajewski J, Accili D (2007) A Foxo/Notch pathway controls myogenic
1053 differentiation and fiber type specification. Journal of Clinical Investigation 117:2477–
1054 2485. doi: 10.1172/JCI32054

1055 28. Kurashige T, Morino H, Murao T, Izumi Y, Sugiura T, Kuraoka K, Kawakami H, Torii
1056 T, Maruyama H (2022) TDP-43 Accumulation Within Intramuscular Nerve Bundles of
1057 Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol 79:693–701. doi:
1058 10.1001/JAMANEUROL.2022.1113

1059 29. Lasa-Elgarresta J, Mosqueira-Martín L, González-Imaz K, Marco-Moreno P, Gerenu G,
1060 Mamchaoui K, Mouly V, López de Munain A, Vallejo-Illarramendi A (2022) Targeting
1061 the Ubiquitin-Proteasome System in Limb-Girdle Muscular Dystrophy With CAPN3
1062 Mutations. Front Cell Dev Biol 10:822563. doi: 10.3389/fcell.2022.822563

1063 30. Latil M, Rocheteau P, Châtre L, Sanulli S, Mémet S, Ricchetti M, Tajbakhsh S, Chrétien
1064 F (2012) Skeletal muscle stem cells adopt a dormant cell state post mortem and retain
1065 regenerative capacity. Nat Commun 3. doi: 10.1038/ncomms1890

1066 31. Link W, Fernandez-Marcos PJ (2017) FOXO transcription factors at the interface of
1067 metabolism and cancer. Int J Cancer 141:2379–2391. doi: 10.1002/ijc.30840

1068 32. Liu TY, Chen YC, Jong YJ, Tsai HJ, Lee CC, Chang YS, Chang JG, Chang YF (2017)
1069 Muscle developmental defects in heterogeneous nuclear Ribonucleoprotein A1 knockout
1070 mice. Open Biol 7. doi: 10.1098/RSOB.160303

1071 33. Loeffler J-P, Picchiarelli G, Dupuis L, Gonzalez De Aguilar J-L (2016) The Role of
1072 Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathol 26:227–36. doi:
10.1111/bpa.12350

1074	34.	Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion
1075		for RNA-seq data with DESeq2. Genome Biol 15. doi: 10.1186/s13059-014-0550-8

- 1076 Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, Burden SJ, 35. Di Lisi R, Sandri C, Zhao J, Goldberg AL, Schiaffino S, Sandri M (2007) FoxO3 controls 1077 1078 autophagy in skeletal muscle in vivo. Cell Metab 6:458-471. doi: 10.1016/J.CMET.2007.11.001 1079
- Manzano R, Toivonen JM, Calvo AC, Oliván S, Zaragoza P, Rodellar C, Montarras D,
 Osta R (2013) Altered in vitro Proliferation of Mouse SOD1-G93A Skeletal Muscle
 Satellite Cells. Neurodegener Dis 11:153–164. doi: 10.1159/000338061
- 1083 37. Martin LJ, Wong M (2020) Skeletal Muscle-Restricted Expression of Human SOD1 in
 1084 Transgenic Mice Causes a Fatal ALS-Like Syndrome. Front Neurol 11:592851. doi:
 10.3389/fneur.2020.592851
- 1086 38. Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J
 1087 Neurol 27:1918–1929. doi: 10.1111/ene.14393
- McFarlane C, Plummer E, Thomas M, Hennebry A, Ashby M, Ling N, Smith H, Sharma
 M, Kambadur R (2006) Myostatin induces cachexia by activating the ubiquitin
 proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J Cell
 Physiol 209:501–514. doi: 10.1002/jcp.20757
- 40. Milan G, Romanello V, Pescatore F, Armani A, Paik J-H, Frasson L, Seydel A, Zhao J,
 Abraham R, Goldberg AL, Blaauw B, DePinho RA, Sandri M (2015) Regulation of
 autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network
 during muscle atrophy. Nat Commun 6:6670. doi: 10.1038/ncomms7670
- Moloney EB, de Winter F, Verhaagen J (2014) ALS as a distal axonopathy: Molecular
 mechanisms affecting neuromuscular junction stability in the presymptomatic stages of
 the disease. Front Neurosci 8. doi: 10.3389/fnins.2014.00252
- Mori F, Tada M, Kon T, Miki Y, Tanji K, Kurotaki H, Tomiyama M, Ishihara T, Onodera
 O, Kakita A, Wakabayashi K (2019) Phosphorylated TDP-43 aggregates in skeletal and
 cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis
 and various conditions. Acta Neuropathol Commun 7. doi: 10.1186/s40478-019-0824-1
- 1103 43. Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, Shimokawa T,
 1104 Shibasaki M (2010) Discovery of novel Foxo1 inhibitors for treating type 2 diabetes:

1105 1106		Improvement of fasting glycemia in diabetic db/db mice. Molecular Pharmacology Fast Forward Published on August 24. doi: 10.1124/mol.110.065714
1107	44.	Nakashima K, Yakabe Y (2007) AMPK activation stimulates myofibrillar protein
1108		degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO
1109		transcription factors in C2C12 myotubes. Biosci Biotechnol Biochem 71:1650–1656. doi:
1110		10.1271/BBB.70057
1111	45.	Nath SR, Lieberman ML, Yu Z, Marchioretti C, Jones ST, Danby ECE, Van Pelt KM,
1112		Sorarù G, Robins DM, Bates GP, Pennuto M, Lieberman AP (2020) MEF2 impairment
1113		underlies skeletal muscle atrophy in polyglutamine disease. Acta Neuropathol 140:63-80.
1114		doi: 10.1007/S00401-020-02156-4

- 1115 46. Nishiyama T, Kii I, Kudo A (2004) Inactivation of Rho/ROCK signaling is crucial for the
 1116 nuclear accumulation of FKHR and myoblast fusion. J Biol Chem 279:47311–47319. doi:
 10.1074/JBC.M403546200
- 1118 47. Olguín HC, Pisconti A (2012) Marking the tempo for myogenesis: Pax7 and the
 1119 regulation of muscle stem cell fate decisions. J Cell Mol Med 16:1013–1025. doi:
 1120 10.1111/j.1582-4934.2011.01348.x
- 48. Orea-Soufi A, Paik J, Bragança J, Donlon TA, Willcox BJ, Link W (2022) FOXO
 transcription factors as therapeutic targets in human diseases. Trends Pharmacol Sci
 43:1070–1084. doi: 10.1016/j.tips.2022.09.010
- 49. Oyabu M, Takigawa K, Mizutani S, Hatazawa Y, Fujita M, Ohira Y, Sugimoto T, Suzuki
 O, Tsuchiya K, Suganami T, Ogawa Y, Ishihara K, Miura S, Kamei Y (2022) FOXO1
 cooperates with C/EBPδ and ATF4 to regulate skeletal muscle atrophy transcriptional
 program during fasting. FASEB J 36. doi: 10.1096/FJ.202101385RR
- 50. Pala F, Di Girolamo D, Mella S, Yennek S, Chatre L, Ricchetti M, Tajbakhsh S (2018)
 Distinct metabolic states govern skeletal muscle stem cell fates during prenatal and
 postnatal myogenesis. J Cell Sci 131. doi: 10.1242/JCS.212977
- 1131 51. Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch S, Henriques A,
 Boutillier A-L, Zoll J, Echaniz-Laguna A, Loeffler J-P, René F (2015) A metabolic
 switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse
 model of amyotrophic lateral sclerosis. EMBO Mol Med 7:526–46. doi:
 10.15252/emmm.201404433

1136	52.	Pandya	VA, Patani F	R (2020) Decoding	the relationship	between	ageing and amyotre	ophic
1137		lateral	sclerosis:	а	cellular	perspective.	Brain	143:1057–1072.	doi:
1138		10.1093	/BRAIN/AW	Z360					

- 1139 53. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C (2017) Salmon provides fast and
 bias-aware quantification of transcript expression. Nat Methods 14:417–419. doi:
 10.1038/nmeth.4197
- 1142 54. Pietrangelo T, Demontis R, Santangelo C, Pini N, Bonelli M, Rosato E, Roberti P,
 1143 Locatelli M, Tartaglia A, Marramiero L, Verratti V, Bondi D, Fulle S, D'Aloja E,
 1144 D'Ovidio C (2022) New Perspectives for Postmortem Human Satellite Cells of Different
 1145 Embryological Origin. Front Physiol 13. doi: 10.3389/FPHYS.2022.886149
- 1146 55. Pikatza-Menoio O, Elicegui A, Bengoetxea X, Naldaiz-Gastesi N, López de Munain A,
 1147 Gerenu G, Gil-Bea FJ, Alonso-Martín S (2021) The Skeletal Muscle Emerges as a New
 1148 Disease Target in Amyotrophic Lateral Sclerosis. J Pers Med 11:671. doi:
 10.3390/JPM11070671
- 56. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC,
 Sun E, Wancewicz E, Mazur C, Kordasiewicz H, Sedaghat Y, Donohue JP, Shiue L,
 Bennett CF, Yeo GW, Cleveland DW (2011) Long pre-mRNA depletion and RNA
 missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci
 14:459–468. doi: 10.1038/NN.2779
- 57. Pradat P-F, Barani A, Wanschitz J, Dubourg O, Lombès A, Bigot A, Mouly V, Bruneteau
 G, Salachas F, Lenglet T, Meininger V, Butler-Browne G (2011) Abnormalities of
 satellite cells function in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis
 12:264–271. doi: 10.3109/17482968.2011.566618
- 1159 58. Puthanveetil P, Wang Y, Wang F, Kim MS, Abrahani A, Rodrigues B (2010) The
 1160 increase in cardiac pyruvate dehydrogenase kinase-4 after short-term dexamethasone is
 1161 controlled by an Akt-p38-forkhead box other factor-1 signaling axis. Endocrinology
 1162 151:2306–18. doi: 10.1210/en.2009-1072
- 1163 59. Relaix F, Zammit PS (2012) Satellite cells are essential for skeletal muscle regeneration:
 1164 the cell on the edge returns centre stage. Development 139:2845–2856. doi:
 1165 10.1242/dev.069088
- 1166 60. REYNOLDS ES (1963) The use of lead citrate at high pH as an electron-opaque stain in
 1167 electron microscopy. J Cell Biol 17:208–212. doi: 10.1083/JCB.17.1.208

1168	61.	Rico A, Guembelzu G, Palomo V, Martínez A, Aiastui A, Casas I fraile L, Valls A, de
1169		Munain AL, Sáenz A (2021) Allosteric Modulation of GSK-3 β as a New Therapeutic
1170		Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. Int J Mol Sci 22.
1171		doi: 10.3390/IJMS22147367

1172 62. Rico A, Valls A, Guembelzu G, Azpitarte M, Aiastui A, Zufiria M, Jaka O, López de
1173 Munain A, Sáenz A (2023) Altered expression of proteins involved in metabolism in
1174 LGMDR1 muscle is lost in cell culture conditions. Orphanet J Rare Dis 18. doi:
10.1186/S13023-023-02873-5

1176 63. Rion N, Castets P, Lin S, Enderle L, Reinhard JR, Eickhorst C, Ruegg MA (2019) mTOR
1177 controls embryonic and adult myogenesis via mTORC1. Development 146. doi:
10.1242/DEV.172460

1179 64. Rossor AM, Sleigh JN, Groves M, Muntoni F, Reilly MM, Hoogenraad CC, Schiavo G
(2020) Loss of BICD2 in muscle drives motor neuron loss in a developmental form of
spinal muscular atrophy. Acta Neuropathol Commun 8. doi: 10.1186/S40478-020-009096

Sambasivan R, Yao R, Kissenpfennig A, van Wittenberghe L, Paldi A, Gayraud-Morel B,
Guenou H, Malissen B, Tajbakhsh S, Galy A (2011) Pax7-expressing satellite cells are
indispensable for adult skeletal muscle regeneration. Development 138:3647–3656. doi:
10.1242/DEV.067587

1187 66. Sanchez AMJ, Candau RB, Bernardi H (2014) FoxO transcription factors: their roles in
the maintenance of skeletal muscle homeostasis. Cell Mol Life Sci 71:1657–1671. doi:
10.1007/S00018-013-1513-Z

Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL,
Spiegelman BM (2006) PGC-1alpha protects skeletal muscle from atrophy by
suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U
S A 103:16260–16265. doi: 10.1073/PNAS.0607795103

1194 68. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S,
1195 Lecker SH, Goldberg AL (2004) Foxo transcription factors induce the atrophy-related
1196 ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399–412. doi:
10.1016/S0092-8674(04)00400-3

1198 69. Scaramozza A, Marchese V, Papa V, Salaroli R, Sorarù G, Angelini C, Cenacchi G
(2014) Skeletal Muscle Satellite Cells in Amyotrophic Lateral Sclerosis. Ultrastruct
Pathol 38:295–302. doi: 10.3109/01913123.2014.937842

1201 70. Scaricamazza S, Salvatori I, Ferri A, Valle C (2021) Skeletal muscle in als: An
1202 unappreciated therapeutic opportunity? Cells 10:1–24. doi: 10.3390/cells10030525

1203 71. Schiaffino S, Dyar KA, Calabria E (2018) Skeletal muscle mass is controlled by the
1204 MRF4-MEF2 axis. Curr Opin Clin Nutr Metab Care 21:164–167. doi:
1205 10.1097/MCO.0000000000456

1206 Shi XC, Xia B, Zhang JF, Zhang RX, Zhang DY, Liu H, Xie BC, Wang YL, Wu JW 72. 1207 (2022) Optineurin promotes myogenesis during muscle regeneration in mice by 1208 autophagic degradation of GSK3β. PLoS Biol 20. doi: 10.1371/JOURNAL.PBIO.3001619 1209

1210 73. Soneson C, Love MI, Robinson MD (2016) Differential analyses for RNA-seq:
1211 Transcript-level estimates improve gene-level inferences. F1000Res 4. doi:
1212 10.12688/F1000RESEARCH.7563.2/DOI

1213 74. Soulez M, Tanguay PL, Florence D, Dort J, Crist C, Kotlyarov A, Gaestel M, Ferron M,
1214 Dumont NA, Meloche S (2022) ERK3-MK5 signaling regulates myogenic differentiation
1215 and muscle regeneration by promoting FoxO3 degradation. J Cell Physiol 237:2271–
1216 2287. doi: 10.1002/JCP.30695

1217 75. Stallings NR, Puttaparthi K, Dowling KJ, Luther CM, Burns DK, Davis K, Elliott JL
1218 (2013) TDP-43, an ALS linked protein, regulates fat deposition and glucose homeostasis.
1219 PLoS One 8:e71793. doi: 10.1371/journal.pone.0071793

1220 76. Strah N, Romano G, Introna C, Klima R, Marzullo M, Ciapponi L, Megighian A,
1221 Nizzardo M, Feiguin F (2020) TDP-43 promotes the formation of neuromuscular
1222 synapses through the regulation of Disc-large expression in Drosophila skeletal muscles.
1223 BMC Biol 18. doi: 10.1186/S12915-020-00767-7

1224 77. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich
A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis:
A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl
Acad Sci U S A 102:15545–15550. doi: 10.1073/pnas.0506580102

Taylor AA, Fournier C, Polak M, Wang L, Zach N, Keymer M, Glass JD, Ennist DL,
Pooled Resource Open□Access ALS Clinical Trials Consortium (2016) Predicting
disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 3:866–875.
doi: 10.1002/acn3.348

1232 79. Tixier V, Bataille L, Etard C, Jagla T, Weger M, DaPonte JP, Strahle U, Dickmeis T,
1233 Jagla K (2013) Glycolysis supports embryonic muscle growth by promoting myoblast
1234 fusion. Proceedings of the National Academy of Sciences 110:18982–18987. doi:
1235 10.1073/pnas.1301262110

- 1236 80. Tokutake Y, Yamada K, Ohata M, Obayashi Y, Tsuchiya M, Yonekura S (2015) ALS1237 Linked P56S-VAPB Mutation Impairs the Formation of Multinuclear Myotube in C2C12
 1238 Cells. Int J Mol Sci 16:18628–18641. doi: 10.3390/ijms160818628
- 1239 81. Vogler TO, Wheeler JR, Nguyen ED, Hughes MP, Britson KA, Lester E, Rao B, Betta
 1240 ND, Whitney ON, Ewachiw TE, Gomes E, Shorter J, Lloyd TE, Eisenberg DS, Taylor JP,
 1241 Johnson AM, Olwin BB, Parker R (2018) TDP-43 and RNA form amyloid-like myo1242 granules in regenerating muscle. Nature 563:508–513. doi: 10.1038/s41586-018-0665-2
- 1243 82. Wang JW, Brent JR, Tomlinson A, Shneider NA, McCabe BD (2011) The ALS1244 associated proteins FUS and TDP-43 function together to affect Drosophila locomotion
 1245 and life span. J Clin Invest 121:4118–4126. doi: 10.1172/JCI57883
- 1246 83. Wheeler JR, Whitney ON, Vogler TO, Nguyen ED, Pawlikowski B, Lester E, Cutler A,
 1247 Elston T, Betta ND, Parker KR, Yost KE, Voge H, Rando TA, Chang HY, Johnson AM,
 1248 Parker R, Olwin BB (2022) RNA-binding proteins direct myogenic cell fate decisions.
 1249 Elife 11. doi: 10.7554/ELIFE.75844
- 1250 84. Wong M, Martin LJ (2010) Skeletal muscle-restricted expression of human SOD1 causes
 1251 motor neuron degeneration in transgenic mice. Hum Mol Genet 19:2284–2302. doi:
 10.1093/hmg/ddq106
- 1253 85. Xu M, Chen X, Chen D, Yu B, Huang Z (2017) FoxO1: A novel insight into its
 1254 molecular mechanisms in the regulation of skeletal muscle differentiation and fiber type
 1255 specification. Oncotarget 8:10662–10674
- 1256 86. Yang ZJP, Kenzelmann Broz D, Noderer WL, Ferreira JP, Overton KW, Spencer SL,
 1257 Meyer T, Tapscott SJ, Attardi LD, Wang CL (2015) p53 suppresses muscle
 1258 differentiation at the myogenin step in response to genotoxic stress. Cell Death Differ
 1259 22:560–573. doi: 10.1038/CDD.2014.189
- Yucel N, Wang YX, Mai T, Porpiglia E, Lund PJ, Markov G, Garcia BA, Bendall SC,
 Angelo M, Blau HM (2019) Glucose Metabolism Drives Histone Acetylation Landscape
 Transitions that Dictate Muscle Stem Cell Function. Cell Rep 27:3939-3955.e6. doi:
 10.1016/j.celrep.2019.05.092

1264 88. Zhang T, Baldie G, Periz G, Wang J (2014) RNA-Processing Protein TDP-43 Regulates
1265 FOXO-Dependent Protein Quality Control in Stress Response. PLoS Genet 10:e1004693.
1266 doi: 10.1371/journal.pgen.1004693

- 1267 89. Zhao J, Brault JJ, Schild A, Goldberg AL (2008) Coordinate activation of autophagy and
 1268 the proteasome pathway by FoxO transcription factor. Autophagy 4:378–380. doi:
 1269 10.4161/AUTO.5633
- 90. Zibold J, Lessard LER, Picard F, da Silva LG, Zadorozhna Y, Streichenberger N, Belotti
 E, Osseni A, Emerit A, Errazuriz-Cerda E, Michel-Calemard L, Menassa R, Coudert L,
 Wiessner M, Stucka R, Klopstock T, Simonetti F, Hutten S, Nonaka T, Hasegawa M,
 Strom TM, Bernard E, Ollagnon E, Urtizberea A, Dormann D, Petiot P, Schaeffer L,
 Senderek J, Leblanc P (2024) The new missense G376V-TDP-43 variant induces lateonset distal myopathy but not amyotrophic lateral sclerosis. Brain 147. doi:
 10.1093/BRAIN/AWAD410
- 1277 91. Zufiría M, Gil-Bea FJ, Fernández-Torrón R, Poza JJ, Muñoz-Blanco JL, Rojas-García R,
 1278 Riancho J, de Munain AL (2016) ALS: A bucket of genes, environment, metabolism and
 1279 unknown ingredients. Prog Neurobiol 142. doi: 10.1016/j.pneurobio.2016.05.004

1280

1281 FIGURE LEGENDS

1282 Figure 1. Pathological and functional abnormalities of primary myoblasts from ALS 1283 patients. a Representative images of primary myoblasts from ALS patients, both familial (fALS) and sporadic ALS (sALS) and healthy controls (CTRL) stained for Myosin Heavy 1284 1285 Chain (MyHC, green) and DAPI (nuclei, blue). **b** Quantitative scatter plots with bar graphs 1286 showing fusion and differentiation indices of each individual's cells from at least n=31287 independent differentiation assays. The inner plots depict the comparison of the average values 1288 of each ALS patient group (fALS and sALS) with the average values of the CTRL group. c The 1289 correlation plot shows a negative association between age and the differentiation index in CTRL 1290 myoblasts (r = -0.61, p = 0.059), indicating that as age increases, the differentiation index tends 1291 to decrease. In contrast, there is no significant association in ALS myoblasts (r = -0.33, p =1292 0.214). When the outlier value (fALS_2), identified by Grubb's test, is removed, the correlation 1293 in ALS* myoblasts becomes r = 0 (p = 0.520), suggesting no relationship between age and 1294 differentiation index. Bar graphs represent mean \pm SEM. *p < 0.05 compared to the CTRL group 1295 via Mann-Whitney U test. Scale bar: 100 µm. d Representative Western blot images of TDP-43 1296 and FUS proteins in CTRL and ALS proliferative myoblasts, and scatter dot-plots with bar 1297 graphs showing the quantification of protein levels. n=3 per group. *p<0.05 compared to the 1298 CTRL group via Mann-Whitney U test.

1299 Figure 2. Functional consequences of TDP-43 or FUS silencing in the immortalised human

1300 control myoblasts. a Schematic diagram of the myogenic process showing the different phases 1301 under study, as well as the interventions and measures performed. b Representative Western 1302 blot images of TDP-43, FUS, MYOD1 and MYOG in shTDP-43 or shFUS-silenced myoblasts 1303 at 100% confluence (Mb 100%) and at 3 days after fusion (D3), and scatter dot-plots with bar 1304 graphs showing the quantification of protein levels. n=3-6 transductions per group. c 1305 Representative images of human immortalised myoblasts stained for MyHC (Myosin heavy 1306 chain, green) and DAPI (nuclei, blue), and quantitative scatter plots with bar graphs showing 1307 fusion and differentiation indices. Immunofluorescence was performed 8 days (D8) after the 1308 first fusion events of shRNA cells. Scale bar: 100 µm. n=6-11 images per group. d Proliferation 1309 curve measured as the fold-change in the number of DAPI-positive nuclei at days 1, 3 and 5 1310 after cell seeding. n= 4-5 images per group. e Representative Western blot images of Atrogin-1 and MURF1 in TDP-43- or shFUS-silenced myoblasts at Mb 100%, and scatter plots with bar 1311 1312 graphs showing the quantification of protein levels. n=3 infections per group. Bar graphs 1313 represent mean \pm SEM. *p<0.05; **p<0.01 compared to the shRNA group via one-way 1314 ANOVA. a.u., arbitrary units.

1315 Figure 3. Metabolic alterations of TDP-43 or FUS silencing in the immortalised human control myoblasts. a Schematic diagram of the myogenic process illustrating the different 1316 1317 phases under study, as well as the intervention point for glycolysis repression and the measures 1318 performed throughout the experiment. **b** Representative images of myogenic differentiation 1319 following 2-deoxyglucose (2-DG) treatment at day 3 after fusion (D3). Myoblasts were stained 1320 for Myosin Heavy Chain (MyHC, green) and DAPI (nuclei, blue). Scale bar: 100 µm. c MYOG 1321 protein expression after 2-DG treatment at 100% confluence (Mb 100%). Representative images 1322 of myoblasts stained for MYOG (red) and DAPI (blue). Scatter plots with bar graphs quantify 1323 the percentage of MYOG-positive nuclei. ImageJ software (v2.9) was used to quantify the 1324 images, with DAPI staining defining the nuclear boundaries. A nucleus was considered positive 1325 for MYOG if its staining intensity was greater than the mean +1*SD of the control (CTRL) 1326 values. n = 6-7 images per group. Scale bar: 100 µm. d MYOD protein expression after 2-DG 1327 treatment at Mb 100%. Representative images of myoblasts stained for MYOD (red) and DAPI 1328 (blue). n = 6-7 images per group. Scale bar: 100 µm. e Representative Western blot images of 1329 MYOD and Atrogin-1 protein levels, and scatter dot-plots with bar graphs showing the 1330 quantification of protein levels. Myoblasts were treated with 2-DG at Mb 100%. n = 31331 treatments per group. Data are expressed as mean \pm SEM. *p<0.05; **p<0.01 compared to the 1332 Mb 100% group via Mann-Whitney U test. a.u., arbitrary units; CTRL, untreated control. f-h 1333 Graphs for Extracellular Acidification Rate (ECAR) (f), Oxygen Consumption Rate OCR (g), and ATP production rate (h) of silenced myoblasts (shRNA, shTDP-43 or shFUS). The 1334 1335 corresponding quantification of basal glycolysis, glycolytic capacity, glycolytic reserve, basal 1336 respiration, maximal respiration, and spare respiration are presented on the right side of panels 1337 (f) and (g), respectively. Analyses were performed one day after seeding myoblasts at Mb 1338 100%. n = 4, 3, and 1 independent experiments, respectively. gluc, Glucose; olig, Oligomycin; 1339 FCCP, Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone; rot/AA, Rotenone/Antimycin A. Bar graphs represent mean \pm SEM. *p < 0.05; **p < 0.01 compared to the shRNA group via 1340 1341 one-way ANOVA.

1342 Figure 4. FOXO transcription factors and related signalling pathways are dysregulated 1343 upon TDP-43 or FUS silencing. a Venn diagram illustrates the number of overlapped 1344 differentially expressed genes (DEGs) between the shTDP-43 and the shFUS-silenced 1345 myoblasts at 100% confluence. b Scatterplot for log₂-transformed fold changes of the 1346 overlapping DEGs, showing a significant correlation between shTDP-43 and shFUS-silenced mvoblasts. R² and linear function are indicated in the graph. Genes upregulated and 1347 1348 downregulated in both datasets are indicated in red and blue, respectively. The grey shade area 1349 represents the 95% confidence interval. c Bubble chart of ranked enrichment analysis of shTDP-1350 43 plotted against shFUS gene expression signatures using the Hallmark database by the GSEA

1351 multilevel enrichment test; GSEA score rank is based on normalised enrichment score (NES) 1352 and $-\log_{10}$ FDR *p*-value for each gene set. Bubble size represents the average $-\log_{10}$ FDR *p*-1353 value. Gene sets upregulated and downregulated in both shTDP-43 and shFUS myoblasts are 1354 indicated in red and blue, respectively. Enrichment analysis of gene expression signatures using 1355 KEGG, GO Biological Process and GO Molecular Function can be viewed in Supplementary Fig. 7. d Common transcription factors (TF) across the shTDP-43 and shFUS myoblasts with 1356 1357 predicted significant activity change by ISMARA motif analysis (based on Z score and average 1358 gene target expression change). MYOG/TCF3, MYOD1 and MEF2A/C/D are highlighted 1359 among the TF motifs with downregulated target gene expression change (left panel). FOXO1/6, 1360 CREB1, TP53, MZF1 and PRDM1 are highlighted among the TF motifs with upregulated target 1361 gene expression change (right panel). e Representative images of human control immortalised 1362 myoblasts at 100% confluence stained for FOXO1 (green) and DAPI (nuclei, blue), and scatter 1363 dot-plot with a bar graph showing the percentage of cells positive for nuclear FOXO1 staining. 1364 Quantification was made with ImageJ v2.9 software using DAPI staining to delimit nuclei. Nuclei with integrated density values above the cut-off point (set as the value of mean +1*SD of 1365 1366 shRNA cells) were considered positive for FOXO1. Scale bars: 50 µm. n=6-9 images per cell 1367 line. Scale bar: 25 µm. n=3-4 images per group, 2 independent experiments. *p<0.05, **p<0.011368 compared to the shRNA group via one-way ANOVA.

1369 Figure 5. FOXO1 inhibition corrects myogenic defects and metabolic derangements 1370 induced by deficiency of TDP-43 or FUS. a Representative images of TDP-43 or FUS-1371 knockdown myoblasts treated or not with shFOXO1 lentiviral particles and stained for MyHC 1372 (Myosin heavy chain, green) and DAPI (nuclei, blue). Quantitative scatter plots with bar graphs 1373 showing differentiation and fusion indices (right). Scale bar: 50 μ m. n=5-6 images per group. **b** 1374 Representative images of TDP-43 or FUS-knockdown myoblasts treated or not with the 1375 selective FOXO1 inhibitor AS1842856 (iFOXO1) at 30 nM and stained for MyHC (green) and 1376 DAPI (blue). Quantitative scatter plots with bar graphs showing differentiation and fusion indices (right). Immunofluorescence was performed 8 days (D8) after the first fusion events of 1377 1378 shRNA control cells. Scale bar: 50 µm. n=5-6 images per group. c Representative Western blot 1379 images of MYOD1 and MYOG protein levels in shTDP-43 or shFUS-silenced myoblasts at 1380 100% confluence (Mb 100%) treated with iFOXO, and scatter dot-plots with bar graphs 1381 showing the quantification of protein levels. n=3-6 transductions per group. a.u., arbitrary units. 1382 d Representative graphs showing Extracellular Acidification Rate (ECAR) of TDP-43 or FUS-1383 knockdown myoblasts treated or not with the selective iFOXO1 at 30 nM, and the basal 1384 glycolysis and basal respiration calculated by the data obtained in these analyses. Analyses were 1385 performed one day after seeding myoblasts at Mb 100%. n=3 independent experiments. Bar 1386 graphs represent mean \pm SEM. *p < 0.05; **p < 0.01 compared to the shRNA control group via

one-way ANOVA; [#]p<0.05; ^{##}p<0.01 compared to the non-treated group via one-way ANOVA.
gluc, Glucose; olig, Oligomycin; 2-DG, 2-deoxyglucose; OCR, Oxygen Consumption Rate,
FCCP, Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone; rot/AA, Rotenone/Antimycin
A.

1391 Figure 6. FOXO1 is dysregulated in primary myoblasts from ALS patients and its 1392 inhibition alleviates myogenic defects. a FOXO1 protein expression in myoblasts from ALS 1393 patients and controls. Left panel: Representative images of primary myoblasts at 100% 1394 confluence (Mb100%) from ALS patients, both familial (fALS) and sporadic ALS (sALS), and 1395 healthy controls (CTRL) stained for FOXO1 (green) and DAPI (nuclei, blue). Right panel 1396 shows a dual representation of FOXO1 staining: scatter plot showing the distribution of cells 1397 positive for nuclear FOXO1 (top), and bar graph depicting the mean optical density (OD) of 1398 cytosolic FOXO1 staining (bottom). Quantifications were done using ImageJ v2.9 software. 1399 DAPI staining was used to define nuclear boundaries. Nuclei with a staining intensity greater 1400 than the mean +1*SD of CTRL values were considered positive for FOXO1. The inner plots 1401 depict the comparison of the average values of each ALS patient group (fALS and sALS) with 1402 the CTRL group. Bar graphs represent mean \pm SEM. n = 3-5 images per group. *p < 0.051403 compared to CTRL via Mann-Whitney U test. Scale bars: 100 µm. b Effect of FOXO1 1404 inhibition on myogenic differentiation. Left panel: Representative images of primary myoblasts 1405 from ALS patients and CTRLs, treated or not (NT) with the selective FOXO1 inhibitor 1406 AS1842856 (iFOXO1) at 30 nM, stained for Myosin Heavy Chain (MyHC, green) and DAPI 1407 (nuclei, blue). Right panel: Quantitative scatter plot with bar graphs showing fusion and 1408 differentiation indices. Immunofluorescence was performed 8 days (D8) after the first fusion 1409 events observed in untreated CTRL cells. Scale bars: 100 μ m. n = 5-6 images per group. Bar 1410 graphs represent mean \pm SEM. *p<0.05 compared to the NT group via Mann-Whitney U test. c 1411 Effect of FOXO1 inhibition on glycolysis in primary myoblasts. Representative graphs show 1412 the Extracellular Acidification Rate (ECAR) of primary myoblasts from a selection of ALS patients and an age-matched healthy CTRLs, treated or not with the selective iFOXO1 at 30 1413 1414 nM. The basal glycolysis and glycolytic capacity were calculated based on these analyses. 1415 Analyses were performed one day after seeding myoblasts at 100% confluence. n = 3independent experiments. Bar graphs represent mean \pm SEM. *p<0.05, **p<0.01 compared to 1416 1417 the NT CTRL group via one-way ANOVA; ##p<0.01 compared to the NT group via one-way 1418 ANOVA. gluc, Glucose; olig, Oligomycin; 2-DG, 2-deoxyglucose.

Figure 7. FOXO1 inhibitor AS1842856 treatment reverses phenotypical-functional
parameters in *Drosophila melanogaster* models with muscle-conditioned TDP-43/FUS
downregulation. a Schematic illustration of the different fly models used in this study and the

1422 analyses performed. Flies were orally treated (feeding) with the FOXO1 inhibitor AS1842856 1423 (iFOXO1) from the larval stage onwards. b Scatter dot-plots with median and interquartile 1424 range showing climbing activity of the different fly models on adult days 5, 10 and 15. n=51425 flies per tube, 10 tubes per group. Each value is calculated as the average of three trials. 1426 *p < 0.05; **p < 0.01 compared to control (CTRL) flies via one-way ANOVA. c Kaplan-Meier 1427 curves of *caz*- or *TBPH*-silenced flies. n=100 flies per group; **p<0.01 compared to any of the 1428 knockdown flies via log-rank test. d Scatter dot-plots with median and interquartile range 1429 showing climbing activity of the different fly models treated with iFOXO1 at 30 μ M. n= 5 flies 1430 per tube, 9 tubes per group. Each value is calculated as the average of three trials. *p < 0.05; 1431 **p < 0.01 compared to non-treated flies via two-way ANOVA. e-g Kaplan-Meier curves of *caz*-(e) or TBPH-silenced flies (f-g) treated (feeding) with iFOXO1. n=90 flies per group. *p < 0.05; 1432 1433 **p<0.01 compared to non-treated flies via log-rank test. h Representative images of pharate lethality in the fly model *iTBPH*^{*pkk(108354)*} with or without treatment (feeding) with iFOXO1. 1434 1435 Note that the pupae of CTRL flies are empty and adult flies are at the top of the tube. However, adult pharates of the $iTBPH^{pkk(108354)}$ model remain trapped inside the pupa. The scatter dot-plots 1436 with median and interquartile range in the right shows the effect of iFOXO1 on adult pharate 1437 survival. n= 75 pupae per tube, 6 tubes per group. **p<0.01 compared to non-treated flies via 1438 1439 Student's t test. i Representative images of Drosophila indirect flight muscles stained with 1440 Phalloidin (blue), neuronal marker HRP (pink) and Bruchpilot (green). Scale bar: 50 µm. 1441 Digitally zoomed images show Bruchpilot+ synaptic boutons along motoneuron terminals. j, k 1442 Scatter dot-plots with median and interquartile range shows the quantification of the synaptic 1443 area (j) and neuron (HRP+) density (k). n=12 flies per group. **p<0.01 compared to CTRL flies; $^{\#\#}p<0.01$ compared to *iTBPH*^{*pkk*(108354)} flies via two-way ANOVA. 1444

1445

1446 SUPPLEMENTARY INFO

1447 Supplementary Tables:

- 1448 Supplementary Table 1: Primary antibodies.
- 1449 Supplementary Table 2: DEGs of shTDP-43 and shFUS myoblasts from RNA-seq experiment.
- 1450 Supplementary Table 3: GO and KEGG enriched pathways of shTDP-43 and shFUS myoblasts
- 1451 from RNA-seq experiment.
- 1452 Supplementary Table 4: ISMARA TF motifs analysis.

1453 Supplementary Figures:

- 1454 Supplementary Figure 1. Haematoxylin and eosin staining for ALS and control muscle sections.
- 1455 Supplementary Figure 2. Further characterization of primary myoblasts from ALS patients.
- 1456 Supplementary Figure 3. Examination of cytoplasmic granules of TDP-43 and FUS in ALS
- 1457 primary human myoblasts.
- Supplementary Figure 4. Ultrastructural characteristics of human myoblasts with TDP-43 orFUS silencing.
- Supplementary Figure 5. Dynamics of TDP-43 and FUS along the myogenic process in theimmortalised human myoblasts.
- 1462 Supplementary Figure 6. Metabolic characterization of the immortalised human myoblasts.
- 1463 Supplementary Figure 7. Extended Figure 4c. a-c
- Supplementary Figure 8. Dynamics of FOXO transcription factors throughout myogenesis andmetabolic challenges in human myoblasts.
- 1466 Supplementary Figure 9. Levels of nuclear FOXO3 in myoblasts models of ALS.
- 1467 Supplementary Figure 10. Effect of FOXO1 silencing on the levels of nuclear FOXO1 in human
- 1468 myoblasts silenced for TDP-43 or FUS.
- Supplementary Figure 11. FOXO1 is not dysregulated in primary myoblasts from non-ALSneurogenic atrophies and myopathies.

1471 Supplementary Figure 12. Extended Fig. 7.

1472 Supplementary Videos:

- 1473 Supplementary Video 1. Locomotor activity test in non-treated (NT) CONTROL flies
- 1474 Supplementary Video 2. Locomotor activity test in non-treated (NT) iCaz flies
- 1475 Supplementary Video 3. Locomotor activity test in iFOXO1-treated iCaz flies
- 1476 Supplementary Video 4. Locomotor activity test in non-treated (NT) iTBPH^{attp40} flies
- 1477 Supplementary Video 5. Locomotor activity test in iFOXO1-treated iTBPH^{attp40} flies
- 1478 Supplementary Video 6. Locomotor activity test in non-treated (NT) iTBPH^{p(GD6943)} flies
- 1479 Supplementary Video 7. Locomotor activity test in iFOXO1-treated iTBPH^{p(GD6943)} flies

1480

a









medRxiv preprint doi: https://doi.org/10.1101/2024.07.17.24309945; this version posted July 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

C









RNAseq Analysis of myogenic capacity Metabolic fitness shRNA Š shTDP-43 Mb 30% Mb 100% Fusion **D8** D3 shFUS

MYOG - D3 Mb 100% **TDP-43** - Mb100% FUS - Mb100% MYOD1 - Mb100% **D**3







0

Ŏ

S.O



**



C



2

~















S.A.

2:00





Glycolytic Reserve

**

15-

101

5-

5





ATP production rate

2:00

X

C

Ω

TF motif analysis - downregulated

 \square

^

C

Mb 100%

MYOD1 - Mb100%

MYOG - Mb100%

Glycolysis

Basal Glycolysis

Mitochondrial ATP

b

^

CTRL

CTRL+iFOXO1
 iTBPH^{pkk(108354)}
 iTBPH^{pkk(108354)} +iFOXO1